Document:

Exhibit
10.2

 

ANNEXURE
C TO DEED OF AMENDMENT/ SCHEDULE 6 TO BID IMPLEMENTATION AGREEMENT

 

CONTINGENT
VALUE RIGHTS AGREEMENT

 

THIS
CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [●] [●], 2021 (this “Agreement”), is
entered into by and among Wize Pharma, Inc., a Delaware corporation (the “Company,” or “Wize”),
Wize NC, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Wize US”), OcuWize
Ltd., a company incorporated under the laws of the state of Israel and a wholly owned subsidiary of Wize US (“OcuWize”),
[●], as the Holders’ Representative (as defined herein), [●], as Rights Agent (the “Rights Agent”)
and as initial CVR Registrar (as defined herein).

 

RECITALS

 

WHEREAS,
the Company and Cosmos Capital Limited (ACN 636 458 912), an Australian company (“Cosmos”), have entered
into a Bid Implementation Agreement, dated as of December 30, 2020 (as amended on January [●], 2021 and as it may be further
amended or supplemented from time to time pursuant to the terms thereof, the “Acquisition Agreement”),
pursuant to which the Company conducted the Offer to acquire all the outstanding shares of Cosmos (the “Acquisition”);

 

WHEREAS,
the Company desires to enter into this Agreement and issue one non-transferrable CVR with respect to each CVR Eligible Security
outstanding as of the Record Date; and

 

WHEREAS,
each of the Company and the Wize Subsidiaries has done all things necessary to make the CVRs, when issued pursuant to this Agreement,
the valid obligations of the Wize Subsidiaries, and to extent set forth herein, the Company;

 

NOW,
THEREFORE, it is mutually covenanted and agreed, for the equal and proportionate benefit of all Holders, as follows:

 

Article
I.   DEFINITIONS

 

Section
1.01  For all purposes of this Agreement, except as otherwise expressly
provided or unless the context otherwise requires:

 

(a) 
 the terms defined in this Article I have the meanings assigned to them in this Article I, and include the plural as well
as the singular;

 

(b) 
all accounting terms used herein and not expressly defined herein shall have the meanings assigned to such terms in accordance
with United States generally accepted accounting principles (U.S. GAAP), as in effect on the date hereof;

 

(c) 
the words “herein,” “hereof” and “hereunder” and other words of similar import refer to this
Agreement as a whole and not to any particular Article, Section or other subdivision;

 

(d) 
unless the context otherwise requires, words describing the singular number shall include the plural and vice versa, words denoting
any gender shall include all genders and words denoting natural Persons shall include corporations, partnerships and other Persons
and vice versa;

 

(e) 
all references to “including” shall be deemed to mean including without limitation;

 

(f) 
unless the context otherwise requires, if the doing of any act, matter or thing under this Agreement is dependent on the consent
or approval of a party or is within the discretion of a party and the consent or approval or discretion is qualified by the words
“not to be unreasonably withheld”, it shall mean not to be unreasonably withheld, conditioned or delayed; and

 

(g) 
all references to an undertaking by Wize or Wize Subsidiaries to use “commercially reasonable efforts” shall be deemed
to mean that Wize or Wize Subsidiaries, as applicable, shall also cause its Affiliates to do so, and it being clarified that neither
the potential payment of the CVR Payment Amounts under this Agreement to CVR Holders, nor the lack of any economic interest to
Wize Subsidiaries or Wize in the LO2A Transactions (other than reimbursement of the Transaction Expenses) shall be taken into
account in determining the level of efforts to be exerted to take the applicable action.

 

    

     

    

 

Section
1.01  Capitalized terms used but not otherwise defined herein shall
have the respective meanings ascribed thereto in the Acquisition Agreement. The following terms shall have the meanings ascribed
to them as follows:

 

“Affiliate”
means, with respect to any specified Person, any other Person who or which, directly or indirectly, controls, is controlled by,
or is under common control with such specified Person, including, without limitation, any general partner, limited partner, member,
officer, director or manager of such Person and any venture capital or private equity fund now or hereafter existing that is controlled
by one or more general partners or managing members of, or shares the same management company with, such Person. For purposes
of this definition, the terms “controls,” “controlled by,” or “under common control
with” means the possession, direct or indirect, of power to direct or cause the direction of management or policies
(whether through ownership of voting securities, by contract or otherwise). For the sake of clarity, the Wize Subsidiaries are
deemed Affiliates of the Company.

 

“BBG”
means Bonus BioGroup Ltd.

 

“BBG
Exchange Agreement” means that Exchange Agreement, dated as of January 9, 2020, between BBG and the Company, as
amended and supplemented from time to time, including by that Addendum to Exchange Agreement, dated as of December 30, 2020, by
and among BBG, Wize, the Wize Subsidiaries and Wize IL.

 

“BBG
Expenses” means the sums payable to BBG under the BBG Exchange Agreement.

 

“Board”
means the board of directors of the Company. 

 

“Business
Day” means any day other than a Saturday, Sunday or a day on which banking institutions in New York, New York are
authorized or obligated by law or executive order to remain closed.

 

“Common
Stock” means the shares of common stock of the Company, par value $0.001 per share. 

 

“CVR
Derivative Security” means any security of the Company exercisable or convertible into Common Stock, the terms of
which provide for an adjustment, in the event of any distribution like the CVR, by way of participation in such distribution,
as is conclusively determined by the Board, and notified in writing to Rights Agent, at least three (3) Business Days prior to
the Record Date.

 

“CVR
Eligible Security” means, as of the Record Date, (i) each outstanding share of Common Stock and (ii) each outstanding
CVR Derivative Security. 

 

“CVR
Quarter” means the period beginning on the Effective Time and ending on the end of the first calendar quarter in
which the Effective Time occurs, and, thereafter, each full calendar quarter (January 1 through March 31; April 1 to June 30;
July 1 to September 30; and October 1 through December 31 of each year) until the calendar quarter ending immediately after the
Termination Date (e.g., if the Termination Date falls on February 1, 2023, then the last CVR Quarter shall be the one ended on
March 30, 2023).

 

“CVRs”
means contingent value rights issued by Wize pursuant to this Agreement, pursuant to which the Holders are to receive contingent
cash payments or other consideration pursuant to this Agreement, and each is referred to individually as a “CVR.” 

 

    -2-

     

    

 

“Effective
Time” means the date and time on which the Closing Date (as defined in the Acquisition Agreement) occurs. 

 

“Holder”
means a Person in whose name a CVR is registered in the CVR Register. 

 

“Holders’
Representative” means the representative of the Holders named in the preamble, until a successor Holders’
Representative shall have become such pursuant to the applicable provisions of this Agreement, and thereafter “Holders’
Representative” shall mean such successor Holders’ Representative.

 

“Intellectual
Property Rights” means any and all intellectual property rights, including without limitation (i) patents and patent
applications, including all reissues, renewals, reexaminations, extensions, supplementary protection certificates or equivalents
thereof, continuations, divisions, and continuations-in-part thereof; (ii) copyrights and all other rights corresponding thereto
throughout the world; (iii) rights associated with trademarks, service marks, trade names, trade dress, domain names, logos
and similar rights, and the goodwill associated therewith, whether registered or unregistered; (iv) trade secrets and know-how;
and (viii) any similar, corresponding or equivalent rights to any of the foregoing anywhere in the world, including the right
to seek remedies against infringements thereof and rights of protection of an interest therein under the laws of all jurisdictions. 

 

“Last
CVR Entitlement Date” means the last date on which an entitlement (including entitlement for any escrow, earnout
or other contingent payment) arises to receive consideration under any LO2A Transaction Agreement.

 

“LO2A
Advisor Agreements” means engagement letter agreements of either the Company, its Affiliates or the Holders’
Representative with investment bankers, legal counsel and other professional advisors that Holders’ Representative believes,
in good faith, will help facilitate exploring, pursuing and/or consummating an LO2A Transaction.

 

“LO2A
Business” means the business of monetizing any LO2A Product or use or development or other exploitation of the LO2A
Technology or of any of the Company’s rights therein, directly or indirectly.

 

“LO2A
Product” means (i) any product, that comprise, contain or incorporate, in whole or in part, LO2A Technology, (ii)
the development, production and/or sale of which is based on, or involves, in whole or in part, the use of LO2A Technology, (iii)
products which are produced or manufactured, in whole or in part, using a process, method or system covered by, or falling within,
the LO2A Technology, or (iv) any other use, commercialization and/or exploitation of the LO2A Technology in any manner whatsoever
and for any purpose or indication whatsoever with respect to all of the foregoing.

 

“LO2A
Technology” means any invention, know-how or other Intellectual Property Rights owned by or licensed to Wize and/or
any of its Affiliates prior to, on and/or after the date hereof in connection with, based on and/or as a result of the use of
the formula developed by Resdevco for the treatment of dry eye syndrome, and other ophthalmological illnesses, including Conjunctivochalasis
and Sjögren’s syndrome, but specifically excludes: (a) any invention, know-how or other Intellectual Property Rights
owned by or licensed to Cosmos and/or any of its Affiliates prior to the date hereof, (b) any invention, know-how or other Intellectual
Property Rights owned by or licensed to Cosmos and/or any of its Affiliates on or following the date hereof in connection with
digital asset infrastructure or in connection with any other business that is not related to the LO2A Business, and (c) rights
associated with trademarks, service marks, trade names, trade dress, domain names, logos and similar rights, and the goodwill
associated therewith, whether registered or unregistered, of the name “Wize Pharma” or similar variations that do
not include the LO2A Business; provided however that, in the event of an LO2A Transaction that involves the sale of any Wize Subsidiary,
the LO2A Transaction Agreement may provide that the acquiror may keep using the corporate name of such subsidiaries for up to
90 days after consummation of such LO2A Transaction.

 

    -3-

     

    

 

“Majority
of CVR Holders” means, as of any date, written consent of the Holders holding a majority of the outstanding CVRs
as of such date (or, if at the Holders’ Representative decision, a meeting of the Holders of CVRs is convened in order to
obtain the approval of the Holders hereunder, the Holders of a majority of the outstanding CVRs as of such date that are present
and voting, by person or proxy, at such meeting); for this purpose, CVRs beneficially owned by the Company or by any Affiliate
of the Company shall be considered as though not outstanding.  

 

“Officer’s
Certificate” means a certificate signed by the chief executive officer, president or chief financial officer of
the applicable party in his or her capacity as such, and delivered to the Rights Agent.

 

“Permitted
Liabilities” mean (A) costs, obligations or liabilities that would constitute Transaction Expenses, (B) obligations
or liabilities (as opposed to costs) that are immaterial in nature, taking into account that the primary business of the Company
following the Closing is not related to the LO2A Business, and (C) costs, obligations or liabilities that are executory in nature
and are primarily related to the corporate existence of the Company or the Wize Subsidiaries or the due authorization (and required
third party consents) of the action being authorized and/or representations and warranties regarding, if applicable, financial
statements of the Company or the Wize Subsidiaries (subject to customary materiality qualifications) if such financial statements
cover periods beyond the Effective Time. 

 

“Permitted
Transfer” means a transfer of one or more CVRs (i) upon death of a Holder by will or intestacy, (ii) by instrument
to an inter vivos or testamentary trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee, (iii)
pursuant to a court order; (such as in connection with divorce, bankruptcy or liquidation), (iv) if the Holder is a partnership
or limited liability company, a distribution by the transferring partnership or limited liability company to its partners or members,
as applicable; (v) a transfer made by operation of law (including a consolidation or merger) or in connection with the dissolution,
liquidation or termination of any corporation, limited liability company, partnership or other entity; provided that
as a condition to any such transfer, in each case, any such transferee shall take each such CVR subject to the terms and conditions
of this Agreement and, if requested by the Company, shall sign and deliver to the Rights Agent a written instrument agreeing to
be subject to and bound by the terms and conditions of this Agreement. 

 

“Person”
means any natural person, corporation, partnership, limited liability company, trust, estate, other firm or entity or governmental
body. 

 

“Resdevco”
means Resdevco Ltd.

 

“Resdevco
Agreement” means that Exclusive Distribution and Licensing Agreement between Wize IL (including OcuWize) and Resdevco,
dated as of May 1, 2015, as amended and supplemented from time to time.

 

“Resdevco
Expenses” means the sums payable to Resdevco under the Resdevco Agreement and the sums of any reasonable out of
pocket expenses associated with or arising out of performing any and all obligations arising out of the Resdevco Agreement.

 

“Rights
Agent” means the Rights Agent named in the Preamble to this Agreement, until a successor Rights Agent shall have
become such pursuant to the applicable provisions of this Agreement, and thereafter “Rights Agent” shall mean such
successor Rights Agent. 

 

    -4-

     

    

 

“Transaction
Expenses” means the following to the extent incurred by Wize or any of the Wize Subsidiaries after the Effective
Time and prior to the applicable measurement date (i.e., prior to the scheduled distribution of the CVR Payment Amount); provided
that any following item is documented and without double counting: (i) the Post-Closing LO2A Investment actually incurred and
paid; (ii) all taxes incurred and paid (and that are not otherwise credited or offset) by the Company or its Affiliates during
the relevant period and that are a direct result from the consummation of the LO2A Transaction (such as transfer taxes, if any);
(iii) all out of pocket transaction expenses (including any broker fees, accountant or attorney’s fees) incurred by the
Company or any of its Affiliates as a result of an LO2A Transaction; provided such transaction expenses (or the terms of engagement
therefor) were previously approved in writing by the Holders’ Representative (not to be unreasonably withheld); (iv) any
costs or expenses relating to the Company’s obligations under Sections 3.03(g), 3.03(h), 5.04
and/or 5.05; (v) the Resdevco Expenses; provided that no amendment to the Resdevco Agreement was made following the
Effective Time without the prior written approval of the Holders’ Representative; (vi) the BBG Expenses; provided that no
amendment to the BBG Exchange Agreement was made following the Effective Time without the prior written approval of the Holders’
Representative; (vii) all reasonable attorney fees expended or incurred in connection with reviewing any actions to be taken by
the Company at the request by the Holders’ Representative; (viii) all costs and expenses for the W&I Insurance or the
Indemnity Escrow, if applicable; and (ix) such other liabilities, costs or expenses that the Holders’ Representative or
the Majority of CVR Holders agree to be treated as Transaction Expenses. For the sake of clarity, unless otherwise expressly agreed
otherwise, any costs and expenses incurred by the Company or its Affiliates in compliance with this Agreement or arising from
any dispute arising therefrom shall not be considered Transaction Expenses.

 

“Wize
IL” means Wize Pharma Ltd., an Israeli limited company and a wholly owned subsidiary of Wize.

 

“Wize
Subsidiaries” mean Wize US, OcuWize, and, without derogating from the Company’s obligations hereunder (including
Section 4.03), any other subsidiary of the Company or Wize US to the extent it holds, directly or indirectly, any equity interest
in OcuWize Ltd.

 

Article
II.  CONTINGENT VALUE RIGHTS; LO2A TRANSACTION

 

Section
2.01 Issuance of CVRs; Appointment of Rights
Agent.

 

(a) 
At the Effective Time, Wize shall issue to Holders one CVR for each CVR Eligible Security held of record by such Holder as of
4:01 p.m. Eastern Time on the day immediately before the Effective Time (the “Record Date”).

 

(b) 
Wize hereby appoints the Rights Agent in accordance with the express terms and conditions of this Agreement, and the Rights Agent
hereby accepts such appointment.

 

(c) 
Distribution of any CVR Payment Amount to Holders shall be made in accordance with such Holder’s proportion of the aggregate
outstanding CVRs as reflected in the CVR Register from time to time.

 

Section
2.02  Nontransferable.

 

The
CVRs shall not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole
or in part, other than through a Permitted Transfer. Any attempted sale, assignment, transfer, pledge, encumbrance or disposition
of any CVR or any right or interest therein, in whole or in part, in violation of this ‎Section 2.02 shall be
void ab initio and of no effect. The CVRs will not be listed on any quotation system or traded on any securities exchange.

 

Section
2.03  No Certificate; Registration; Registration of Transfer; Change
of Address.

 

(a) 
The CVRs shall be issued in book-entry form only and shall not be evidenced by a certificate or other instrument.

 

(b) 
The Company shall furnish or cause to be furnished to the Rights Agent in such form as the Company receives from its transfer
agent (or other agent performing similar services for the Company), and which is reasonably satisfactory to the Rights Agent,
the names, addresses and numbers of CVR Eligible Security held as of the Record Date of those Persons entitled to receive CVRs
pursuant to this Agreement.

 

    -5-

     

    

 

(c) 
The Rights Agent shall keep a register (the “CVR Register”) for the registration of CVRs. The Rights
Agent is hereby initially appointed as the CVR registrar and transfer agent (“CVR Registrar”) for the
purpose of registering CVRs and transfers of CVRs as herein provided. Upon any change to the identity of the Rights Agent in accordance
with the terms of this Agreement, the successor Rights Agent shall automatically also become the successor CVR Registrar.

 

(d) 
Subject to the restrictions on transferability set forth herein, every request made to transfer a CVR must be in writing and accompanied
by a written instrument or instruments of transfer and accompanied by a signature guarantee and such other documentation as the
Rights Agent or CVR Registrar may reasonably request, duly executed by the registered Holder or Holders thereof or by the duly
appointed legal representative, personal representative or survivor of such Holder or Holders or by a duly authorized attorney-in-fact,
setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt of such written request and materials,
the CVR Registrar shall, subject to its reasonable determination that the transfer instrument is in proper form, register the
transfer of the CVRs in the CVR Register. All duly transferred CVRs registered in the CVR Register shall remain the valid obligations
of the Wize Subsidiaries, and to extent set forth herein, the Company, evidencing the same right and shall entitle the transferee
to the same benefits and rights under this Agreement, as those previously held by the transferor. No transfer of a CVR shall be
valid until registered in the CVR Register, and any transfer not duly registered in the CVR Register will be void ab initio. Any
transfer or assignment of the CVRs shall be without charge (other than the cost of any transfer tax which shall be the sole responsibility
of the transferor) to the Holder; it being clarified that the Rights Agent may charge the Company a fee therefor in accordance
with this Agreement.

 

(e) 
A Holder may make a written request to the CVR Registrar to change such Holder’s address of record in the CVR Register.
The written request must be duly executed by the Holder. Upon receipt of such written notice, the CVR Registrar shall promptly
record the change of address in the CVR Register.

 

Section
2.04  LO2A Transaction; CVR Payment Amount.

 

(a) 
During the period commencing on the Effective Time and ending on the earlier of (i) the LO2A Termination Date (as defined below)
and (ii) the second-year anniversary of the Effective Time (the “Transaction Term”), each of the Company
and the Wize Subsidiaries hereby authorizes (and shall cause the Wize Subsidiaries, if any are formed and for so long as they
have not countersigned this Agreement, to authorize) the Holders’ Representative, and the Holders’ Representative
hereby agrees to use its good faith efforts, to pursue, explore, discuss and negotiate the terms of a transaction, or a series
of transactions (whether related or not), for the monetization of the Wize Subsidiaries’ rights in the LO2A Technology,
including through (i) a sale of any of the Wize Subsidiaries to a third party and/or (ii) partnering, licensing, sublicensing,
distribution, reselling or sale of all or any part of the LO2A Technology or LO2A Products to a third party (each, an “LO2A
Transaction”). The Holders’ Representative shall be solely authorized for all matters and actions in respect
of (i) any LO2A Transaction, including identifying appropriate third parties, negotiating with such third parties and, subject
to Section 2.04(b), executing and consummating any LO2A Transaction, (ii) in connection therewith, any decision
to amend or modify the Resdevco Agreement and/or the BBG Exchange Agreement, so long as such amendment or modification does not
impose any additional cost, obligation or liability on the Company (other than Permitted Liabilities) and, subject to Section 2.04(b),
executing and consummating such amendment(s) or modification(s) (the “Resdevco/BBG Amendment”), and (iii) terminating
the Resdevco Agreement, if no LO2A Transaction Agreement is entered prior to such termination decision (the date such termination
becomes effective, the “LO2A Termination Date”). Without derogating from the generality of the foregoing, Wize
shall (i) empower the Holders’ Representative to designate any and all members of the Board of Directors of Wize US (and,
thereby, OcuWize), and (ii) empower the Holders’ Representative to manage, or designate any other person who will manage,
Wize ownership rights in Wize US in view of the interests of the Holders and in accordance with this Agreement and the BBG Exchange
Agreement; provided that the foregoing should not be construed as imposing any additional obligations on Wize beyond those
expressly specified in the this Agreement. The Wize Subsidiaries, and to extent necessary, the Company, shall provide reasonable
assistance to the Holders’ Representative in respect of any LO2A Transaction, Resdevco/BBG Amendment, and/or such termination
decision, including providing the Holders’ Representative with reasonable access to the Company’s and its Affiliates’
books, records, documents, personnel and other reasonably requested information; provided that if such information is not readily
in the possession of the Company or its Affiliates and would require the preparation of any information, the costs and reasonable
expenses therefor would be considered Transaction Expenses if the Company so informs the Holders’ Representative in writing
prior thereto.

 

    -6-

     

    

 

(b) Without
derogating from Section 4.04 below, each of the Wize Subsidiaries, and to extent necessary, the Company, undertakes to provide
reasonable support (and shall cause the Wize Subsidiaries, including those not countersigning this Agreement, to support), the
cost of which support, if (x) requires the support of any third parties or the devotion of substantial internal resources and
(y) the Company so informs the Holders’ Representative in writing prior thereto, shall be considered Transaction Expenses,
(i) any proposed LO2A Transaction presented by the Holders’ Representative and to approve entry into such transaction (including
causing the execution of the LO2A Transaction Agreement), (ii) any LO2A Advisor Agreements presented by the Holders’ Representative
(including causing the execution thereof), and (iii) any proposed Resdevco/BBG Amendment presented by the Holders’ Representative
and to approve entry into such transaction (including causing the execution of any Resdevco/BBG Amendment), unless the Company
shall have reasonably determined that such LO2A Transaction Agreement, LO2A Advisor Agreements or Resdevco/BBG Amendment, as the
case may be, would subject the Company to (A) any additional cost or expense that would not constitute a Transaction Expense,
or (B) any other liability for which Company would not be indemnified, in each case, other than Permitted Liabilities. Notwithstanding
anything to the contrary herein, it is hereby agreed that unless Company consents in writing otherwise, which it may withhold
in its good faith discretion, the terms for any LO2A Transaction must provide that, other than Permitted Liabilities, the Company
is not liable for the breach of any representation, warranty or covenant made in connection with the LO2A Transaction, except
to the extent that the liability for such breach is paid solely (i) out of an escrow established with LO2A Consideration to cover
breach of representations, warranties and covenants of Company (the “Indemnity Escrow”), (ii) by representation
and warranty or warranty and indemnity insurance (or a similar product) (“W&I Insurance”) purchased in
connection with the LO2A Transaction with LO2A Consideration, and/or (iii) out of any earn-out, contingent payment or similar
payment of the LO2A Consideration ) after Company has reimbursed itself for all Transaction Expenses.

 

(c) If
(i) the Wize Subsidiaries and, to extent applicable, the Company shall have complied with its obligations hereunder and (ii) the
Wize Subsidiaries and, to extent applicable, the Company shall not have entered into a definitive binding agreement in respect
of an LO2A Transaction (an “LO2A Transaction Agreement”) during the Transaction Term, then, any time
thereafter the Board may, in its good faith discretion, elect to terminate this Agreement or, if so requested in writing by the
Holders’ Representative, the parties shall terminate this Agreement (the date of such election, the “Program
Termination Date”); in which case, the Company shall provide written notice of such termination to the Rights Agent
and the Holders’ Representative. This Agreement and all CVRs shall terminate automatically, and without any action on the
part of the Company, the Wize Subsidiaries, the Rights Agent, any Holder, the Holders’ Representative or any other Person,
on the Program Termination Date.

 

(d) 
The Wize Subsidiaries, and to extent applicable, the Company shall promptly deliver (or cause its Affiliates to deliver) to the
Rights Agent for the ratable benefit of the Holders, in accordance with the payment procedures set forth in Section 2.06,
any consideration (whether cash, stock, assets or otherwise) that the Wize Subsidiaries, or to extent applicable, the Company
(or any of its Affiliates or shareholders) received in connection with the LO2A Transaction Agreement(s) (“LO2A Consideration”)
net of all Transaction Expenses not previously reimbursed to the Company or any of its Affiliates (such net consideration distributed,
a “CVR Payment Amount”). If any LO2A Consideration (i) received by the Wize Subsidiaries, or to extent
applicable, the Company (or any of its Affiliates or shareholders) is a combination of cash and non-cash consideration, then the
Wize Subsidiaries, or to extent applicable, the Company may, at its election, set off all Transaction Expenses first against the
cash portion of such LO2A Consideration before distributing any CVR Payment Amount pursuant to this Section 2.04(d),
or (ii) consists of funds or other consideration that are placed in escrow or are contingent, then the LO2A Consideration (and
consequently, the CVR Payment Amount) shall initially be calculated without such escrowed funds and/or contingent consideration,
and once released or otherwise received by the Wize Subsidiaries or, to extent applicable, the Company (or any of its Affiliates
or shareholders), it shall be calculated as part of the LO2A Consideration (and consequently, the CVR Payment Amount).

 

    -7-

     

    

 

Section
2.05  Payment Procedures.

 

(a) Within
ten (10) Business Days following receipt of any LO2A Consideration by the Wize Subsidiaries, or to the extent applicable, by Wize,
Wize shall deliver to the Rights Agent (x) an Officer’s Certificate certifying the CVR Payment Amount, if any, received
by the Wize Subsidiaries, or to the extent applicable, Wize (or its Affiliates), with a copy to the Holders’ Representative
(the “CVR Certificate”) and (y) the CVR Payment Amount. If the CVR Payment Amount is to be paid in cash,
then such amount will be transferred by wire transfer of immediately available funds to an account designated in writing by the
Rights Agent, the applicable CVR Payment Amount, if any. To the extent that any CVR Payment Amount is paid to the Rights Agent,
such amounts shall be treated for all purposes of this Agreement as having been paid to the Holders and any delay, failure or
mistake in payment by Rights Agent shall not be the liability or obligation of Wize or the Wize Subsidiaries, as applicable (it
being clarified such delay, failure or mistake in payment by Rights Agent being treated, and subject to the liability limitations,
set forth in Article III). If the Wize Subsidiaries, or to the extent applicable, the Company fails to timely deliver the CVR
Payment Amount (as may be adjusted upwards following resolution of a disagreement underlying a Notice of Objection) due hereunder
to the Rights Agent, other than due to reasons which are a ‘force majeur’ or act of God, then, without derogating
from the other rights and remedies available herein, such CVR Payment Amount shall bear a default interest of 6% per annum (from
the date it was due until the transfer date) and such default interest shall be added to, and become part of, the CVR Payment
Amount.

 

(b) On
or prior to the 10th Business Day immediately following delivery of the CVR Certificate and the applicable CVR Payment
Amount to the Rights Agent in accordance with Section 2.05, the Rights Agent shall (i) send each Holder a copy of such CVR Certificate
to such Holder’s registered address and (ii) distribute the CVR Payment Amount, if any, to the Holders pro rata in accordance
with their respective CVRs as reflected on the CVR Register, by checks (if such payment is to be made in cash) mailed to the respective
addresses of such Holders as reflected in the CVR Register (the earlier of such 10th Business Day and the date on which
the Rights Agent distributes the CVR Payment in accordance with this subsection(b), in each case if a CVR Payment Amount shall
have been required to be delivered to the Rights Agent in accordance with Section 2.05, the “CVR Payment Date”).

 

(c)
 The Wize Subsidiaries, or to the extent applicable, Wize shall be entitled to deduct
and withhold, or cause to be deducted or withheld, from each CVR Payment Amount otherwise payable pursuant to this Agreement,
such amounts as Wize or the applicable subsidiary of Wize is required to deduct and withhold with respect to the making of such
payment under the U.S. Internal Revenue Code of 1986, as amended, or any provision of state, local or foreign tax law. To the
extent that amounts are so withheld or paid over to or deposited with the relevant governmental entity, such withheld amounts
shall be treated for all purposes of this Agreement as having been paid to the Holders in respect of which such deduction and
withholding was made. The Wize Subsidiaries, or to the extent applicable, the Company and the Holders’ Representative may
agree to defer any payment of the CVR Payment Amount as needed to secure a tax ruling or other procedure that would allow Wize
to refrain from deducting or reduce the amount to be deducted, at source from the CVR Payment Amount.

 

(d)
 Any portion of a CVR Payment Amount that remains undistributed by the Rights Agent to
the Holders (including by means of uncashed checks or invalid addresses on the CVR Register) twelve (12) months after the relevant
CVR Payment Date shall be delivered by the Rights Agent to Wize, and any Holder shall thereafter look only to Wize for payments
of such CVR Payment Amount, without interest, but such Holder shall have no greater rights against Wize than those accorded to
general unsecured creditors of Wize under applicable law. Neither Wize nor the Rights Agent shall be liable to any Holder in respect
of any cash delivered to a public official in compliance with any applicable state, federal or other abandoned property, escheat
or similar law. If any checks delivered pursuant to the provisions hereof shall not have been cashed prior to the date on which
the cash in respect of such checks would otherwise escheat to or become the property of any governmental authority, any cash in
respect of such checks shall, to the extent permitted by law, immediately prior to such time become the property of Wize. Thereafter,
Wize shall be responsible for compliance with unclaimed property obligations.

 

    -8-

     

    

 

Section 2.06. 
Reporting.

 

(a) 
If the Company shall not have delivered a CVR Certificate pursuant to Section 2.05 in any CVR Quarter, then, no later than 15
days following the end of such CVR Quarter, the Company shall deliver to the Rights Agent, with a copy to the Holders’ Representative,
an Officer Certificate indicating that no CVR Payment Amount was due in respect of such CVR Quarter (a “Non-Achievement
Certificate”). The Rights Agent shall promptly (and in no event later than ten (10) Business Days after receipt
thereof) send each Holder a copy of the Non-Achievement Certificate at the address reflected in the CVR Register as of the date
the Rights Agent received such Non-Achievement Certificate.

 

(b) 
Upon written demand by the Majority of CVR Holders (which demand must be in writing, with a copy to the Holders’ Representative
and the Rights Agent) or the Holders’ Representative within thirty (30) calendar days after either (i) distribution
by the Rights Agent of a Non-Achievement Certificate or (ii) distribution by the Rights Agent of a CVR Certificate (the “Objection
Period”), the Holders’ Representative shall deliver a written notice to Wize (i) specifying that the Holders’
Representative or Majority of CVR Holders objects to the determination and/or calculation of Wize set forth in the Non-Achievement
Certificate or CVR Certificate, as applicable, and (ii) setting forth in reasonable detail the basis upon which the Holders’
Representative or Majority of CVR Holders have determined that a CVR Payment Amount is in fact payable for the applicable CVR
Quarter or that the amount of the CVR Payment Amount should be higher, as applicable (a “Notice of Objection”).
Any dispute arising from a Notice of Objection shall be resolved in accordance with the procedure set forth in Section 8.06, which
decision shall be binding on the parties hereto and every Holder; it being clarified that the delivery of a Notice of Objection
shall not relieve the Wize Subsidiaries or, to extent the applicable, the Company from payment of the CVR Payment Amount set forth
in its initial CVR Certificate.

 

(c) 
If a Notice of Objection has not been delivered to Wize within the Objection Period, then the Non-Achievement Certificate or CVR
Certificate, as applicable, shall not be subject to any challenge by the Holders’ Representative or any Holder, and the
Rights Agent shall have no further obligations with respect to such Non-Achievement Certificate or CVR Certificate, as applicable.

 

(d)
 Wize shall promptly furnish (and in no event later than ten (10) Business Days
after receipt of a written request) to the Rights Agent and the Holders’ Representative all information and documentation
in connection with this Agreement and the CVRs that the Rights Agent or the Holders’ Representative may reasonably request
in connection with the determination of whether a CVR Payment Amount is due and the sum thereof, which information shall be used
solely in connection with this Agreement and the transactions contemplated hereby and shall be subject to the obligations set
forth in Section 8.14.

 

Section 2.07. No
Voting, Dividends or Interest; No Equity or Ownership Interest in Wize.

 

(a) 
The CVRs shall not have any voting or dividend rights, and, except as expressly set forth otherwise herein, interest shall not
accrue on any amounts payable, if any, on the CVRs to any Holder.

 

(b) 
The CVRs shall not represent any equity or ownership interest in the Company. The rights of the Holders are limited to those expressly
set forth in this Agreement, and Holders’ sole right to receive property hereunder is the right to receive CVR Payment Amounts,
if any, through the Rights Agent in accordance with the terms hereof. It is hereby acknowledged and agreed that a CVR shall not
constitute a security of Wize.

 

    -9-

     

    

 

(c) 
By accepting a CVR, each Holder is deemed to acknowledge and agree to the appointment and authority of the Holders’ Representative
to act as the exclusive representative, agent and attorney-in-fact of such Holder and all Holders as set forth in this Agreement.
By accepting a CVR, each Holder agrees that such Holder will not challenge or contest any action, inaction, determination or decision
of the Holders’ Representative or the authority or power of the Holders’ Representative and will not threaten, bring,
commence, institute, maintain, prosecute or voluntarily aid any action, which challenges the validity of or seeks to enjoin the
operation of any provision of this Agreement, including, without limitation, the provisions related to the authority of the Holders’
Representative to act on behalf of such Holder and all Holders as set forth in this Agreement. If a Holder brings, commences,
institutes, maintains, prosecutes or voluntarily aids any such action, then such Holder shall lose all rights under this Agreement
and under such Holder’s CVRs, including, without limitation, the right to receive any payments under this Agreement or in
connection with any CVR.

 

(d) 
The Wize Subsidiaries and Wize may rely upon any written decision, act, consent or instruction of the Holders’ Representative
as being the decision, act, consent or instruction of every Holder. The Wize Subsidiaries and Wize are hereby relieved from any
liability to any Holder for any acts done by them in accordance with such written decision, act, consent or instruction of Holders’
Representative.

 

Section 2.08. Amendments
to LO2A Transaction Agreement.

 

Notwithstanding
anything contained herein to the contrary, neither Wize nor the Wize Subsidiaries or Affiliates thereof shall amend any LO2A Transaction
Agreement, Resdevco Agreement and/or BBG Exchange Agreement, or waive any right thereunder, unless the Holders’ Representative
or the Majority of CVR Holders consents in writing to each such amendment or waiver.

 

Section 2.09. Ability
to Abandon CVRs.

 

A
Holder may at any time, at such Holder’s option, abandon all of such Holder’s remaining rights in a CVR by transferring
such CVR to Wize without consideration therefor.

 

ARTICLE
III.

THE RIGHTS AGENT

 

Section 3.01. Certain
Duties and Responsibilities.

 

(a) 
The Rights Agent shall be authorized and protected and shall not have any liability for, or in respect of any actions taken, suffered
or omitted to be taken by it in connection with this Agreement and the exercise and performance of its duties hereunder, except
to the extent such liability is a result of the willful misconduct, bad faith or gross negligence of the Rights Agent (each as
determined by a final, non-appealable judgment of a court of competent jurisdiction) and subject to the limitations set forth
herein, including section 3.01(b) below. No provision of this Agreement shall require the Rights Agent to expend or risk its own
funds or otherwise incur any financial liability in the performance of any of its duties hereunder or in the exercise of any of
its rights or powers if it believes that repayment of such funds or adequate indemnification against such risk or liability is
not reasonably assured to it. Notwithstanding anything in this Agreement to the contrary, except for a failure to distribute the
CVR Payment Amount, if any, to the Holders pro rata in accordance with their respective CVRs as reflected on the CVR Register,
any liability of the Rights Agent under this Agreement will be limited to the amount of annual fees (excluding any reimbursed
costs and expenses) paid by the Company to the Rights Agent during the twelve (12) months immediately preceding the event for
which recovery from the Rights Agent is being sought.

 

(b) 
Anything to the contrary notwithstanding, in no event will the Rights Agent be (i) liable for special, punitive, or consequential
loss or damages (including, without limitation, lost profits) or (ii) required to take actions that are beyond its express duties
hereunder.

 

(c) 
The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any CVR Holder
with respect to any action or default by the Company, including, without limiting the generality of the foregoing, any duty or
responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the Company.

 

    -10-

     

    

 

Section 3.02. Merger
or Consolidation or Change of Name of Rights Agent.

 

(a) Any
corporation or limited liability company or other entity into which the Rights Agent or any successor Rights Agent may be merged
or with which it may be consolidated, or any corporation or limited liability company or other entity resulting from any merger
or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any corporation or limited liability
company succeeding to the stock transfer or other shareholder services business of the Rights Agent or any successor Rights Agent,
shall be the successor to the Rights Agent under this Agreement without the execution or filing of any paper or any further act
on the part of any of the parties hereto, provided that such corporation or limited liability company or other
entity would be eligible for appointment as a successor Rights Agent under the provisions of Section 3.04. The purchase of all
or substantially all of the Rights Agent’s assets employed in the performance of transfer agent activities shall be deemed
a merger or consolidation for purposes of this Section 3.02. In case at the time such successor Rights Agent shall succeed to
the agency created by this Agreement, any of the CVR Certificates shall still have the full force provided in the CVR Certificates
and in this Agreement.

 

(b) In
case at any time the name of the Rights Agent shall be changed and at such time any of the CVR Certificates shall have not been
delivered, such CVR Certificates shall still have the full force provided in the CVR Certificates and in this Agreement.

 

Section 3.03. Certain
Rights of Rights Agent.

 

(a) 
the Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no
implied duties, covenants or obligations shall be read into this Agreement against the Rights Agent;

 

(b) 
the Rights Agent may rely and shall be authorized and protected in acting or refraining from acting upon any resolution, certificate,
statement, instrument, opinion, report, notice, request, direction, consent, order, power of attorney, endorsement, affidavit,
letter or other paper or document believed by it to be genuine and to have been signed or presented by an officer of the proper
party or parties or upon any written instructions or statements from the Company, the Wize Subsidiaries or the Holders’
Representative (the authorized representatives thereof are all listed in Schedule 3) with respect to any matter relating to its
role as Rights Agent hereunder. The Rights Agent shall not be deemed to have knowledge of any event of which it was supposed to
receive notice thereof hereunder but as to which no notice was provided, and the Rights Agent shall be fully protected and shall
incur no liability for failing to take any action in connection therewith unless and until it has received such notice;

 

(c) 
whenever the Rights Agent shall deem it necessary or desirable that any fact or matter be proved or established before taking,
suffering or omitting any action hereunder, the Rights Agent may request and rely upon an Officer’s Certificate from the
Company with respect to such fact or matter; and such certificate shall be full and complete authorization and protection to the
Rights Agent and the Rights Agent shall incur no liability for or in respect of any action taken, suffered or omitted to be taken
by it under the provisions of this Agreement in reliance upon such certificate. The Rights Agent shall be fully authorized and
protected in relying upon the most recent instructions received from the Company. In the event the Rights Agent believes any ambiguity
or uncertainty exists hereunder or in any notice, instruction, direction, request or other communication, paper or document received
by the Rights Agent hereunder, the Rights Agent, may, in its sole discretion, refrain from taking any action, and shall be fully
protected and shall not be liable in any way to the Company or any other Person for refraining from taking such action, unless
the Rights Agent receives written instructions from the Company, with a concurrent copy to the Holders’ Representative,
that eliminates such ambiguity or uncertainty to the satisfaction of the Rights Agent;

 

(d) 
the Rights Agent may engage and consult with counsel (who may be legal counsel of the Company or an employee or legal counsel
of the Rights Agent) and the Rights Agent may rely on the advice of such counsel or any opinion of counsel in respect of any action
taken, suffered or omitted to be taken by it hereunder in reliance thereon in the absence of willful misconduct, bad faith or
gross negligence on the part of the Rights Agent (as determined by a final, non-appealable judgment of a court of competent jurisdiction);

 

    -11-

     

    

 

(e) 
the permissive rights of the Rights Agent to perform actions enumerated in this Agreement shall not be construed as a duty;

 

(f) 
the Rights Agent shall not be required to give any note or surety in respect of the execution of such powers or otherwise;

 

(g) 
Wize agrees to indemnify the Rights Agent for, and hold the Rights Agent harmless against, any loss, liability, damage, judgment,
fine, penalty, claim, demand, suit, settlement, cost or expense (including, without limitation, the reasonable fees and out-of-pocket
expenses of legal counsel) incurred, absent willful misconduct, bad faith or gross negligence on the part of the Rights Agent
(the occurrence of each as determined by a final, non-appealable judgment of a court of competent jurisdiction), for any action
taken, suffered or omitted to be taken by the Rights Agent in connection with the acceptance and administration of this Agreement,
or the exercise or performance of its duties hereunder, including, without limitation, the reasonable out of pocket costs and
expenses of defending against any claim of liability hereunder and in enforcing this right of indemnification;

 

(h) 
Wize agrees to pay to, and shall be liable for, the Rights Agent fees and expenses in connection with this Agreement (“Rights
Agent Fees and Expenses”), as set forth on Schedule 1 hereto, and further including reimbursement of the
Rights Agent for all taxes and charges, reasonable out-of-pocket expenses and other charges of any kind and nature, including
reasonable fees and expenses of the Rights Agent’s counsel and agent, (other than taxes measured by the Rights Agent’s
net income), paid or incurred by the Rights Agent in connection with the preparation, negotiation, delivery, amendment, administration
and execution by the Rights Agent of this Agreement and its duties hereunder;

 

(i) 
the Rights Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement
or be required to verify the same, but all such statements and recitals are and shall be deemed to have been made by the Company
or Holders’ Representative only, as applicable;

 

(j) 
the Rights Agent shall not have any liability for or be under any responsibility in respect of the validity of this Agreement
or the execution and delivery hereof; nor shall it be responsible for any breach by the Company of any covenant or failure by
the Company to satisfy conditions contained in this Agreement;

 

(k) 
the Company agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and
delivered all such further and other acts, instruments and assurances as may reasonably be required or requested by the Rights
Agent for the carrying out or performing by the Rights Agent of its duties under this Agreement;

 

(l) 
the Rights Agent shall not be subject to, nor be required to comply with, or determine if any Person has complied with, the LO2A
Transaction Agreement or any other agreement between or among any of the Company, the Holders’ Representative or any other
parties hereto, even though reference thereto may be made in this Agreement, or to comply with any notice, instruction, direction,
request or other communication, paper or document other than as expressly set forth in this Agreement;

 

(m) 
the Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either
itself or by or through its attorneys or agents, and the Rights Agent shall not be answerable or accountable for any act, omission,
default, neglect or misconduct of any such attorneys or agents or for any loss to the Company, to the Holders, the Holders’
Representative or any other Person resulting from any such act, omission, default, neglect or misconduct, absent gross negligence
or bad faith in the selection and continued employment thereof (which gross negligence or bad faith must be determined by a final,
non-appealable judgment of a court of competent jurisdiction) and, in the event of arbitration or litigation in connection with
the matters contemplated herein, the Rights Agent may, but shall not be obligated to, engage and consult with tax experts, valuation
firms and other experts and third parties that it, in its sole and absolute discretion, deems appropriate or necessary to enable
it to discharge its duties hereunder;

 

    -12-

     

    

 

(n) 
nothing herein shall preclude the Rights Agent or any of its Affiliates from acting in any other capacity for the Company or for
any other Person; and

 

(o) 
the provisions of ‎0 and this ‎0 shall survive the expiration of the CVRs, the termination
of this Agreement, the payment of any distributions made pursuant to this Agreement, and the resignation, replacement or removal
of the Rights Agent hereunder.

 

Section 3.04. Resignation
and Removal; Appointment of Successor.

 

(a) 
The Rights Agent and any successor Rights Agent may resign and be discharged from its duties under this Agreement at any time
by giving written notice thereof to the Company and the Holders’ Representative, specifying a date when such resignation
shall take effect, which notice shall be sent at least thirty (30) days before the date so specified. The Company may remove the
Rights Agent or any successor Rights Agent at any time by giving written notice thereof to the Rights Agent and the Holders’
Representative specifying a date when such removal shall take effect, which notice shall be sent at least thirty (30) days before
the date so specified. In the event any transfer agency relationship in effect between the Company and the Rights Agent terminates,
the Rights Agent will be deemed to have resigned automatically and be discharged from its duties under this Agreement as of the
effective date of such termination, and the Company shall be responsible for sending any required notice hereunder.

 

(b) 
If the Rights Agent shall resign or be removed or shall otherwise become incapable of acting, the Company shall appoint a successor
to the Rights Agent. If the Company shall fail to make such appointment within a period of thirty (30) days after giving notice
of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights
Agent, then the Holders’ Representative may apply to any court of competent jurisdiction for the appointment of a new Rights
Agent. Any successor Rights Agent, whether appointed by the Company or by such a court, shall be either (a) a Person organized
and doing business under the laws of the United States or of any state of the United States that is authorized under such laws
to exercise corporate trust or stock transfer powers and is subject to supervision or examination by federal or state authority
and that has, along with its Affiliates, at the time of its appointment as Rights Agent a combined capital and surplus that is
similar or higher than the combined capital and surplus of the initial Rights Agent, or (b) an Affiliate of such Person. No Rights
Agent may be an Affiliate of the Company. After appointment, the successor Rights Agent shall be vested with the same powers,
rights, duties and responsibilities as if it had been originally named as Rights Agent without further act or deed; but the predecessor
Rights Agent shall deliver and transfer to the successor Rights Agent any property at the time held by it hereunder, and execute
and deliver any further assurance, conveyance, act or deed necessary for the purpose; provided, that, the predecessor Rights Agent
shall not be required to make any additional expenditure or assume any additional liability in connection with the foregoing.
Not later than the effective date of any such appointment the Company shall file notice thereof in writing with the predecessor
Rights Agent.

 

(c) 
The Company shall give prompt notice to the Holders’ Representative of each resignation and each removal of a Rights Agent
and each appointment of a successor Rights Agent. Such notice shall include the name and address of the successor Rights Agent.
If the Company fails to send such notice within three (3) days after acceptance of appointment by a successor Rights Agent, the
successor Rights Agent shall cause such notice to be mailed at the expense of the Company.

 

Section 3.05. Acceptance
of Appointment by Successor.

 

Every
successor Rights Agent appointed hereunder shall execute, acknowledge and deliver to the Company, the Holders’ Representative
and the retiring Rights Agent (i) an instrument accepting such appointment and (ii) a counterpart of this Agreement, and thereupon
such successor Rights Agent, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts
and duties of the retiring Rights Agent; provided, that upon the request of the Company, the Holders’ Representative
or the successor Rights Agent, such retiring Rights Agent shall execute and deliver an instrument transferring to such successor
Rights Agent all the rights, powers and trusts of the retiring Rights Agent and shall cooperate in the transfer of all relevant
data, including the CVR Register, to the successor Rights Agent.

 

    -13-

     

    

 

ARTICLE
IV.

CERTAIN COVENANTS

 

Section 4.01. List
of Holders.

 

Wize
shall furnish or cause to be furnished to the Rights Agent (with a copy to the Holders’ Representative) (i) with respect
to holders of shares of Common Stock, in such form as Wize receives from its transfer agent (or other agent performing similar
services for Wize), and (ii) with respect to holders of shares of Common Stock, in such form as Wize receives from its transfer
agent (or the names, addresses and holdings of the Company’s holders of Common Stock as of the Record Date, within ten (10)
Business Days after the Effective Time.

 

Section 4.02. Performance
of Agreements.

 

Unless
this Agreement and the CVRs shall have been terminated as provided herein, from and after the date hereof, the Wize Subsidiaries,
or, solely to the extent applicable, Wize will use commercially reasonable efforts to perform all of its obligations under all
LO2A Transaction Agreements, if any. The parties hereto acknowledge that pursuant to the LO2A Transaction Agreements, third parties
may be responsible for, among other things, the development, regulatory filings, marketing and commercialization associated with
the LO2A Technology. Similarly, the Wize Subsidiaries will use commercially reasonable efforts to comply (or, where applicable,
cause its subsidiaries to comply) with the terms of the Resdevco Agreement and the BBG Exchange Agreement.

 

Section 4.03. Operations.

 

Subject
to the terms of this Agreement, including Section 4.04 below, neither Wize nor the Wize Subsidiaries has any obligation to operate
the LO2A Business in order to maximize any CVR Payment Amount; provided, that (A) the Wize Subsidiaries and Wize shall not, directly
or indirectly, take (or omit to take) any actions in bad faith or for the principal purpose of avoiding or reducing the amount
of CVR Payment Amounts payable under this Agreement or restricting their ability to pay the CVR Payment Amounts, and (B) for the
sake of clarity, Wize may not take, or commit to take, any of the following actions without the prior written consent of the Holders’
Representative or the Majority of CVR Holders (i) sell, transfer, encumber or otherwise dispose any shares of Wize US or any other
Wize Subsidiary, (ii) amend or modify the Resdevco Agreement, the BBG Exchange Agreement and/or the Acquisition Agreement, (iii)
use its voting rights in Wize US to affect the amount of any LO2A Consideration, or (iv) use its ownership or voting rights in
Wize US to circumvent or prevent Wize US from satisfying its obligations under this Agreement or the BBG Exchange Agreement.

 

Section 4.04. LO2A
Investment.

 

The
Wize Subsidiaries shall (and shall cause their Affiliates to) invest, at the request of the Holders’ Representative, in
the development of the LO2A Technology, including (i) by continuing the conduct of clinical trials, applying for regulatory approvals
and engaging advisors, and (ii) leasing space in Israel for such business, including all costs, capitalized costs and out of pocket
expenses in connection with the same (the “Post-Closing LO2A Investment”); it being understood and agreed
that any such Post-Closing LO2A Investment includes the license fees payable to Resdevco under the Resdevco Agreement.

 

    -14-

     

    

 

Section
4.05 Books and Records.

 

The
Wize Subsidiaries, and to the extent applicable, Wize shall make commercially reasonable efforts, and shall cause its subsidiaries
to make commercially reasonable efforts to, keep true, complete and accurate records in sufficient detail to enable the Holders’
Representative and its representatives to determine the amounts payable hereunder.

 

Section 4.05. Assignments.

 

Except
as expressly set forth in Sections 3.04 and 5.06, no party hereto may, in whole or in part, assign any of its rights or obligations
under this Agreement without the prior written consent of the other parties.

 

Section 4.06. Maximum
Post-Closing LO2A Investment and Transaction Expenses.

 

The
Wize Subsidiaries shall, at the request and direction of the Holders’ Representative, spend or incur up to US$300,000 of
Post-Closing LO2A Investment and any other Transaction Expenses; provided that, at the request of the Holders’ Representative,
such amount shall not be limited to US$300,000 if (i) the Holders’ Representative shall (or shall cause others to) finance
or commit to finance such excess on terms acceptable to Wize (not to be unreasonably withheld, provided that it shall be reasonable
not to accept any terms that include recourse against Wize, other than Permitted Liabilities), or (ii) in the event that an LO2A
Transaction Agreement is to be executed during the Transaction Term, to the extent that the proceeds payable under the LO2A Transaction
Agreement will likely cover such excess, such as in case of contingent fees payable to financial advisors (and, in which case,
such excess shall, for the sake of clarity, constitute Transaction Expenses), provided further that such amount is only incurred
and not required to be paid out of pocket until the completion of the LO2A Transaction.

 

Section 4.06. Reimbursement
of Transaction Expenses.

 

The
Wize Subsidiaries, and to the extent applicable, Wize, shall be reimbursed (or shall reimburse itself) for all Transaction Expenses
incurred thereby from the LO2A Consideration (or, in the case of the Post-Closing LO2A Investment of up to US$300,000, from its
own resources); provided, however, that the Wize Subsidiaries and, to the extent applicable, Wize shall provide the Holders’
Representative with a report including all Transaction Expenses to be reimbursed or offset (with copies of invoices and reasonable
explanation of the nature of each expense).

  

ARTICLE
V.

THE HOLDERS’ REPRESENTATIVE

 

Section 5.01. Appointment
of Holders’ Representative.

 

By
accepting CVRs, the Holders hereby appoint, authorize and empower the Holders’ Representative to be the exclusive representative,
agent and attorney-in-fact of each Holder, with full power of substitution, to make all decisions and determinations and to act
(or not act) and execute, deliver and receive all agreements, documents, instruments and consents on behalf of and as agent for
each Holder at any time in connection with, and that may be necessary or appropriate to accomplish the intent and implement the
provisions of this Agreement and to facilitate the consummation of the transactions contemplated hereby, including without limitation
for purposes of (i) negotiating and settling, on behalf of the Holders, any dispute that arises under this Agreement after the
Effective Time, (ii) confirming the satisfaction of the Wize Subsidiaries’ and Wize’s obligations under this Agreement,
(iii) negotiating any LO2A Transaction and LO2A Transaction Agreement (including any LO2A Advisor Agreements), (iv) negotiating
any Resdevco/BBG Amendment, (v) negotiating and settling matters with respect to the amounts to be paid to the Holders pursuant
to this Agreement, (vi) decision regarding termination of the Resdevco Agreement, (vii) using any of its other powers and authorities
contemplated by this Agreement, including designation of directors to the boards of directors Wize Subsidiaries, and (viii) negotiating
and entering into any amendment, modification or waiver to this Agreement in accordance with Article VII hereof.

 

    -15-

     

    

 

Section 5.02. Authority.

 

The
appointment of the Holders’ Representative by the Holders pursuant to Section 5.01 is coupled with an interest and may not
be revoked in whole or in part (including, without limitation, upon the death or incapacity of any Holder). Subject to the prior
qualifications, such appointment shall be binding upon the heirs, executors, administrators, estates, personal representatives,
officers, directors, security holders, successors and assigns of each Holder. All decisions of the Holders’ Representative
with respect to the transactions contemplated hereby (including those actions covered under Section 5.01 above) shall be final
and binding on all Holders. Wize, the Wize Subsidiaries and the Rights Agent shall be entitled to rely upon, without independent
investigation, any act, notice, instruction or communication from the Holders’ Representative and any document executed
by the Holders’ Representative on behalf of any Holder and shall be fully protected in connection with any action or inaction
taken or omitted to be taken in reliance thereon. The Holders’ Representative shall not be responsible for any loss suffered
by, or liability of any kind to, the Holders arising out of any act done or omitted by the Holders’ Representative in connection
with the acceptance or administration of the Holders’ Representative’s duties hereunder, unless such act or omission
involves gross negligence or willful misconduct on the part of the Holders’ Representative; it being understood, including
for purposes of Sections 5.03 and 5.04 below, that any decision or act of the Holders’ Representative that is approved by
the Majority of CVR Holders shall be prima facie evidence that the decision or act did not involve gross negligence or
willful misconduct.

 

Section 5.03. Holders’
Representative Liability.

 

(a) 
The Holders’ Representative shall be authorized and protected and shall not have any liability for, or in respect of any
actions taken, suffered or omitted to be taken by it in connection with this Agreement and the exercise and performance of its
duties hereunder, except to the extent such liability is a result of the willful misconduct or gross negligence of the Holders’
Representative (each as determined by a final, non-appealable judgment of a court of competent jurisdiction). No provision of
this Agreement shall require the Holders’ Representative to expend or risk its own funds or otherwise incur any financial
liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers if it believes that
repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it.

 

(b) 
The Holders’ Representative undertakes to perform such duties and only such duties as are specifically set forth in this
Agreement, and no implied duties, covenants or obligations shall be read into this Agreement against the Holders’ Representative.

 

(c) 
The Holders’ Representative may rely and shall be authorized and protected in acting or refraining from acting upon any
resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, power of attorney,
endorsement, affidavit, letter or other paper or document believed by it to be genuine and to have been signed or presented by
an officer of the proper party or parties or upon any written instructions or statements from the Wize Subsidiaries, the Company
or the Rights Agent with respect to any matter relating to its acting as Holders’ Representative. The Holders’ Representative
shall not be deemed to have knowledge of any event of which it was supposed to receive notice thereof hereunder but as to which
no notice was provided, and the Holders’ Representative shall be fully protected and shall incur no liability for failing
to take any action in connection therewith unless and until it has received such notice.

 

(d) 
Whenever the Holders’ Representative shall deem it necessary or desirable that any fact or matter be proved or established
before taking, suffering or omitting any action hereunder, the Holders’ Representative may request and rely upon an Officer’s
Certificate from the Company with respect to such fact or matter; and such certificate shall be full and complete authorization
and protection to the Holders’ Representative and the Holders’ Representative shall incur no liability for or in respect
of any action taken, suffered or omitted to be taken by it under the provisions of this Agreement in reliance upon such certificate.
The Holders’ Representative shall be fully authorized and protected in relying upon the most recent instructions received
from the Company. In the event the Holders’ Representative believes any ambiguity or uncertainty exists hereunder or in
any notice, instruction, direction, request or other communication, paper or document received by the Holders’ Representative
hereunder, the Holders’ Representative, may, in its sole discretion, refrain from taking any action, and shall be fully
protected and shall not be liable in any way to the Company, the Wize Subsidiaries or any other Person for refraining from taking
such action, unless the Holders’ Representative receives written instructions from the Company that eliminates such ambiguity
or uncertainty to the satisfaction of the Holders’ Representative.

 

    -16-

     

    

 

(e) 
The Holders’ Representative may engage and consult with counsel of its selection and the written advice of such counsel
or any opinion of counsel shall be full and complete authorization and protection to the Holders’ Representative in respect
of any action taken, suffered or omitted to be taken by it hereunder in reliance thereon in the absence of willful misconduct
or gross negligence on the part of the Holders’ Representative (as determined by a final, non-appealable judgment of a court
of competent jurisdiction).

 

(f) 
The permissive rights of the Holders’ Representative to perform actions enumerated in this Agreement shall not be construed
as a duty.

 

(g) 
The Holders’ Representative shall not be required to give any note or surety in respect of the execution of such powers
or otherwise.

 

(h) 
The Holders’ Representative shall not be liable for or by reason of any of the statements of fact or recitals contained
in this Agreement or be required to verify the same.

 

(i) 
The Holders’ Representative shall not have any liability for or be under any responsibility in respect of the validity of
this Agreement or the execution and delivery hereof; nor shall it be responsible for any breach by the Wize Subsidiaries or the
Company of any covenant or failure by the Wize Subsidiaries or the Company to satisfy conditions contained in this Agreement.

 

(j) 
The Holders’ Representative shall not be subject to, nor be required to comply with, or determine if any Person has complied
with any other agreement between or among any of the Company, the Wize Subsidiaries, or any other parties hereto (unless the Holders’
Representative is a party thereto), even though reference thereto may be made in this Agreement, or to comply with any notice,
instruction, direction, request or other communication, paper or document other than as expressly set forth in this Agreement.

 

(k) 
The Holders’ Representative may execute and exercise any of the rights or powers hereby vested in it or perform any duty
hereunder either itself or by or through its attorneys or agents, and the Holders’ Representative shall not be answerable
or accountable for any act, omission, default, neglect or misconduct of any such attorneys or agents or for any loss to the Company,
the Wize Subsidiaries, the Holders, the Rights Agent or any other Person resulting from any such act, omission, default, neglect
or misconduct, absent gross negligence in the selection and continued employment thereof (which gross negligence must be determined
by a final, non-appealable judgment of a court of competent jurisdiction) and, in the event of arbitration or litigation in connection
with the matters contemplated herein, the Holders’ Representative may, but shall not be obligated to, engage and consult
with tax experts, valuation firms and other experts and third parties that it, in its sole and absolute discretion, deems appropriate
or necessary to enable it to discharge its duties hereunder.

 

(l) 
 It is acknowledged by each of the parties hereto that the Company and the Wize Subsidiaries have retained Goldfarb Seligman
& Co. (“Sellers’ Counsel”) to act as their counsel in connection with the transactions contemplated
hereby and that Sellers’ Counsel has not acted as counsel for any other Person in connection with the transactions contemplated
hereby and that no other party or Person has the status of a client of the Sellers’ Counsel for conflict of interest or
any other purposes as a result thereof.  The parties hereby agree that, in the event that a dispute arises between the parties
or any of their respective Affiliates and the Holders or the Holders’ Representative or any of its Affiliates, Sellers’
Counsel may represent the Holders and/or the Holders’ Representative in such dispute even though the interests of the Holders
or the Holders’ Representative may be directly adverse to the Company or any of its Affiliates and even though Sellers’
Counsel may have represented the Company or its Affiliates in a matter substantially related to such dispute, and the Company
and its Affiliates hereby waive, on behalf of themselves and each of their Affiliates, any conflict of interest in connection
with such representation by Sellers’ Counsel. Each of the parties further agrees that, as to all pre-Effective Time communications
among Sellers’ Counsel, any of the Company and its Affiliates, and any Holder or Holder’s Representative in the course
of the negotiation, documentation and consummation of the transactions contemplated by this Agreement, the attorney-client privilege,
the expectation of client confidence and all other rights to any evidentiary privilege belong to the Holders’ Representative,
and may be controlled by Holders’ Representative and shall not pass to or be claimed by Cosmos, the Company or any of their
respective Affiliates.  The parties agree to take, and to cause their respective Affiliates to take, all steps reasonably
necessary to implement the intent of this Section 5.03(l).

 

    -17-

     

    

 

Section 5.04. Indemnification

 

(a) 
Wize agrees to indemnify and defend the Holders’ Representative (in this Section 5.04, including any of its family members,
Affiliates, directors, executive officers, shareholders, successors and assigns) for, and hold the Holders’ Representative
harmless against, any loss, liability, damage, judgment, fine, penalty, claim, demand, suit, settlement, cost or expense (including,
without limitation, the reasonable fees and out-of-pocket expenses of legal counsel), incurred without willful misconduct or gross
negligence on the part of the Holders’ Representative (the occurrence of each as determined by a final, non-appealable judgment
of a court of competent jurisdiction), for any action taken, suffered or omitted to be taken by the Holders’ Representative
in connection with the Holders’ Representative’s exercise or performance of its duties hereunder. For the avoidance
of doubt, the Holders’ Representative shall not be deemed to act in willful misconduct or gross negligence or in breach
of this Agreement if it acts in accordance with the written instructions received from the Majority CVR Holders (to the extent
provided for herein) or at the written advice of counsel.

 

(b) 
Promptly (but in any event within seven (7) Business Days) after the receipt by the Holders’ Representative of written notice
of any demand or claim or the commencement of any action, suit, proceeding or investigation, the Holders’ Representative
shall notify the Company thereof in writing; provided, however, that any failure to do so in a timely manner shall not
limit any of the rights of the Holders’ Representative hereunder (except to the extent such failure materially prejudices
the defense of such demand). The Company shall be entitled to participate at its own expense in the defense of any such claim
or proceeding, and, if it so elects at any time after receipt of such notice, it may assume the defense of any suit brought to
enforce any such claim or of any other legal action or proceeding.

 

(c) 
For the avoidance of doubt, it is hereby confirmed and agreed that the Company shall not settle any claim or proceeding in respect
of this Agreement for which the Holders’ Representative is not fully indemnified by the Company under this Agreement without
the prior written consent of the Holders’ Representative, which shall not be unreasonably withheld.

 

(d) 
For the purposes of this Section 5.04, the terms “expense” or “loss” means any amount paid or payable
to satisfy any claim, demand, request, action, suit or proceeding settled with the written consent of the Holders’ Representative,
and all reasonable costs and expenses, including, but not limited to, counsel fees and disbursements, paid or incurred in investigating
or defending against any such claim, demand, action, suit, proceeding or investigation.

 

(e) 
The provisions of Section 5.03 and this Section 5.04 shall survive the expiration of the CVRs, the termination of this Agreement,
the payment of any distributions made pursuant to this Agreement, and the resignation, replacement or removal of the Holders’
Representative hereunder.

 

Section 5.05. Holders’
Representative Fees and Expenses.

 

The
Company agrees to pay, or reimburse the Holders’ Representative promptly for, the Holders’ Representative’s
out of pocket expenses reasonably incurred in connection with this Agreement and the services the Holders’ Representative
provides, including any expense associated with exploring and negotiating any LO2A Transaction as well as all taxes and charges,
reasonable out-of-pocket expenses and other charges of any kind and nature, including reasonable fees and expenses of counsel
to Holders’ Representative (as well as the service fees agreed to below, as applicable) (“Holders’ Representative
Fees and Expenses”). In addition, and without derogating from the other provisions of this Section 5.05, upon the
Successor Holders’ Representative assuming the position of the Holders’ Representative, Holders’ Representative
Fees and Expenses include reimbursement of the Holders’ Representative for all taxes and charges, reasonable out-of-pocket
expenses and other charges of any kind and nature, including reasonable fees and expenses of the Holders’ Representative’s
counsel and agent (other than taxes measured by the Holders’ Representative’s income), paid or incurred by the Holders’
Representative in connection with the discharging of the Holders’ Representative’s duties under this Agreement. The
parties agree that the Company (i) shall not pay the initial Holders’ Representative any fees for its services hereunder
(other than, for the sake of clarity, reimbursement of expenses as set forth above), and (ii) in case any Successor Holders’
Representative is appointed, it shall pay a Successor Holders’ Representative a fee that shall not exceed the customary
fees payable for such services at such time.

 

    -18-

     

    

 

Section 5.06. Successor
Holders’ Representative.

 

(a) 
 The Holders’ Representative and any successor Holders’ Representative may resign and be discharged from its duties
under this Agreement at any time by giving written notice thereof to the Company, specifying a date when such resignation shall
take effect, which notice shall be sent at least 21 days before the date so specified.

 

(b) 
The Holders’ Representative (and any successor thereof) may be removed for any reason or no reason by approval of a Majority
of CVR Holders, but only with the consent of Wize, which will not be unreasonably withheld.

 

(c) 
In the event that the Holders’ Representative dies, becomes unable to perform his or her responsibilities hereunder or resigns
or is removed from such position, a Majority of CVR Holders shall be authorized, with the consent of Wize, which will not be unreasonably
withheld, to and shall select another representative to fill such vacancy and such substituted representative shall be deemed
to be the Holders’ Representative for all purposes of this Agreement; provided however that if the initial Holders’
Representative named herein resigns, then the successor Holders’ Representative replacing the initial Holders’ Representative
named herein may be selected by the initial Holders’ Representative without approval of the Majority of CVR Holders.

 

(d) 
The newly-appointed Holders’ Representative shall notify Wize and the Rights Agent in writing of his or her appointment,
provide evidence that a Majority of CVR Holders approved such appointment and provide appropriate contact information for purposes
of this Agreement. Wize, the Wize Subsidiaries and the Rights Agent shall be entitled to rely upon, without independent investigation,
the identity and validity of such newly-appointed Holders’ Representative as set forth in such written notice. In the event
that within 21 days after the Holders’ Representative dies, becomes unable to perform his or her responsibilities hereunder
or resigns or is removed from such position and no successor Holders’ Representative has been so selected, Wize shall cause
the Rights Agent to notify the Person holding the largest quantity of the outstanding CVRs (and who is not Wize or any Affiliate
of Wize) that such Person is the successor Holders’ Representative, and such person shall be the successor Holders’
Representative hereunder. If such Person notifies the Rights Agent in writing that such Person declines to serve, the Rights Agent
shall forthwith notify the Person holding the next-largest quantity of the outstanding CVRs (and who is not Wize or any Affiliate
of Wize) that such next-largest-quantity Person is the successor Holders’ Representative, and such next-largest-quantity
Person shall be the successor Holders’ Representative hereunder. The Holders are intended third party beneficiaries of this
Section 5.06. If a successor Holders’ Representative is not appointed pursuant to the preceding procedure within sixty (60)
days after the Holders’ Representative dies, becomes unable to perform his or her responsibilities hereunder or resigns
or is removed from such position, Wize shall appoint a successor Holders’ Representative.

 

    -19-

     

    

  

ARTICLE
VI.

ADDITIONAL UNDERTAKINGS

 

Section 6.01. Availability
of Information.

 

The
Company will (i) subject to Section 8.14, provide to the Rights Agent and the Holders’ Representative (as the case may be),
all information in connection with this Agreement, the LO2A Transaction and the CVRs that such person may reasonably request,
and (ii) in the case of any LO2A Transaction, shall publish by way of a press release and/or Form 8-K, the key details thereof.

 

Section 6.02. Consolidation,
Merger, Sale or Conveyance.

 

Without
derogating from the covenants set forth in Section 2.04 and Sections 4.02 to 4.04, in the event that the Wize Subsidiaries or
the Company shall consolidate with or merge into any other Person or convey, transfer or lease any or all of its properties and
assets that relate to LO2A Technology, the Wize Subsidiaries, or to the extent applicable, the Company shall cause the Person
formed by such consolidation or into which the Wize Subsidiaries, or to the extent applicable, the Company is merged or the Person
that acquires by conveyance or transfer, or that leases, such properties and assets of the Company (the “Surviving
Person”) to assume the obligations of the Wize Subsidiaries, or to the extent applicable, the Company under this
Agreement and shall deliver to the Rights Agent written confirmation of the Company and Person that the requirement of this Section
6.2 has been met. It is hereby agreed, however, that if an LO2A Transaction involves the sale of the shares of (i) Wize US, then
Wize US and Ocuwize shall be automatically released from any and all of their rights and obligations hereunder, or (ii) OcuWize,
then Ocuwize shall be automatically released from any and all of its rights and obligations hereunder.

 

Section 6.03. Successor
Substituted.

 

Upon
any consolidation of or merger by the Wize Subsidiaries, or to the extent applicable, the Company with or into any other Person,
or any conveyance, transfer or lease of properties and assets in accordance with Section 6.02, the Surviving Person shall succeed
to, and be substituted for, and may exercise every right and power of, the Wize Subsidiaries, or to the extent applicable, the
Company under this Agreement with the same effect as if the Surviving Person had been named as the Wize Subsidiaries, or to the
extent applicable, the Company herein, and thereafter the predecessor Person shall be relieved of all obligations and covenants
under this Agreement and the CVRs.

    

ARTICLE
VII.

AMENDMENTS

 

Section 7.01. Amendments
Without Consent.

 

(a)
 Without the consent of the Majority of CVR Holders or the Holders’ Representative,
the Company, at any time and from time to time, may enter into one or more amendments hereto, solely for the following purposes
(provided that any amendment effected prior to the Effective Time shall also require the written consent of Cosmos):

 

(i) to
evidence the succession of another Person to the Wize Subsidiaries or the Company and the assumption by any such successor of
the covenants of the Company herein in a transaction contemplated by Section 6.02;

 

(ii) 
to evidence the succession of another Person as a successor CVR Registrar and the assumption by any successor of the obligations
of the CVR Registrar herein;

 

(iii) 
to evidence the succession of another Person as a successor Rights Agent and the assumption by any successor of the covenants
and obligations of the Rights Agent herein;

 

(iv)
as may be necessary or appropriate to ensure that the CVRs are not subject to registration under the Securities Act or the Exchange
Act; provided, that such provisions shall not adversely affect the interests of the Holders and/or to the interests
of the Holders’ Representative; or

 

    -20-

     

    

 

(v)
to add to the covenants of the Company or the Wize Subsidiaries such further covenants, restrictions, conditions or provisions
as the Board shall consider to be for the protection of the Holders; provided, that in each case, such provisions
shall not adversely affect the interests of the Holders and/or to the interests of the Holders’ Representative.

 

 
(b) Any such amendment shall be fully valid even if such amendment is signed only by the Company and the Rights Agent.

 

(c)
Promptly after the execution by the Company and the Rights Agent of any amendment pursuant to the provisions of this Section 7.01,
the Company shall so notify the Holders’ Representative in writing.

 

Section 7.02. Amendments
with Consent.

 

(a) 
Subject to Section 7.01 (which amendments pursuant to Section 7.01 may be made without the consent
of the Holders or the Holders’ Representative), with the written consent of the Holders’ Representative, and subject
to the receipt of the approval of a Majority of CVR Holders, the Company and the Rights Agent (and, prior to the Effective Time,
Cosmos), may enter into one or more amendments hereto (and, for the sake of clarity, the parties hereby agree that any amendment
to the Acquisition Agreement, if made following the Effective Time, shall be deemed as an amendment to this Agreement) for the
purpose of adding, eliminating or changing any provisions of this Agreement, even if such addition, elimination or change is in
any way adverse to the interests of the Holders and/or to the interests of the Holders’ Representative. Any such amendment
shall be fully valid even if such amendment is signed only by the Company and the Rights Agent (and, prior to the Effective Time,
Cosmos), provided, the Holders’ Representative and a Majority of CVR Holders have consented thereto in
writing. Notwithstanding the foregoing, the approval of the Majority of CVR Holders shall not be required if (i) the amendment
is approved by the written consent of the Holders’ Representative and (ii) such amendment, as approved by the Holders’
Representative, does not adversely effect the rights of any Holder in any material respect and does not otherwise treat any Holder
disproportionately and adversely in any respect from all other Holders.

 

(b) 
Promptly after the execution by the Company and the Rights Agent (and, prior to the Effective Time, Cosmos) of any amendment pursuant
to the provisions of this Section 7.02, the Company shall either (i) mail a notice thereof by first-class mail to the Holders
at their respective addresses as they shall appear on the CVR Register, setting forth in general terms the substance of such amendment,
or (ii) publish a notice thereof by way of a press release and/or filing a Form 8-K, setting forth in general terms the substance
of such amendment.

 

Section 7.03. Execution
of Amendments.

 

Before
executing any amendment permitted by this Article VII, the Rights Agent shall be entitled to receive, and shall be fully protected
in relying upon, an opinion of counsel stating that the execution of such amendment is authorized or permitted by this Agreement.
The Rights Agent may, but is not obligated to, enter into any such amendment that affects the Rights Agent’s own rights,
privileges, covenants, immunities, obligations or duties under this Agreement or otherwise. No supplement or amendment to this
Agreement shall be effective unless duly executed by the Rights Agent.

 

Section 7.04. Effect
of Amendments.

 

Upon
the execution of any amendment under this Article VII, this Agreement shall be modified in accordance therewith, such amendment
shall form a part of this Agreement for all purposes and the Holders’ Representative and to the extent valid and binding
under applicable law every Holder shall be bound thereby.

 

    -21-

     

    

 

ARTICLE
VIII.

OTHER PROVISIONS OF GENERAL APPLICATION

 

Section 8.01. Termination.

 

This
Agreement and all CVRs shall terminate automatically and without any action on the part of the Company, the Wize Subsidiaries,
any Holder, the Holders’ Representative, the Rights Agent or any other Person on the earlier of (i) the Program Termination
Date; (ii) 180 days following the Last CVR Entitlement Date (as such period may be extended, in the event of the delivery
of a Notice of Objection, until the final determination thereof in accordance with this Agreement, including, if applicable, the
fulfillment of any payment or other obligation required pursuant to such final determination); and (iii) if the Acquisition Agreement
is validly terminated in accordance with its terms following the date hereof (such earlier date, the “Termination
Date”), and neither this Agreement nor any CVR shall be of any force or effect thereafter, and the Company shall
have no liability hereunder or thereunder, other than with respect to (i) the Wize Subsidiaries, or to the extent applicable,
the Company’s obligation to pay any CVR Payment Amount due and owing to the Holders in accordance with the terms of this
Agreement as of the Termination Date; (ii) the Company’s obligation to pay any amount due and owing by the Company to the
Rights Agent or the Holders’ Representative under this Agreement as of the Termination Date); (iii) any obligation
or liability arising from any prior breach by the Wize Subsidiaries, or to the extent applicable, the Company of any provision
of this Agreement; provided that Sections 3.03(g), 3.03(h), 5.03, 5.04, and this Article VIII shall survive any termination
or expiration of this Agreement and shall remain fully effective and enforceable thereafter.

 

Section 8.02. Notices
to the Rights Agent, the Company and/or the Holders’ Representative.

 

Any
request, demand, authorization, direction, notice, consent, waiver or other document provided or permitted by this Agreement to
the Rights Agent, the Company, the Wize Subsidiaries and/or the Holders’ Representative shall be sufficient for every purpose
hereunder if in writing and delivered personally, sent by email, sent by certified or registered mail (return receipt requested),
sent by first-class mail, postage prepaid or sent by a nationally recognized overnight courier (with proof of service), addressed
as set forth in Schedule 2, and shall be deemed to have been given upon receipt (with confirmation of receipt, if by email).

 

Section 8.03. Notice
to Holders.

 

Where
this Agreement provides for notice to Holders, such notice shall be sufficiently given (unless otherwise herein expressly provided)
if in writing and mailed, first-class postage prepaid, to each Holder affected by such event, at his, her or its address as it
appears in the CVR Register, not later than the latest date, and not earlier than the earliest date, prescribed for the giving
of such notice. In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect
in any notice so mailed, to any particular Holder shall affect the sufficiency of such notice with respect to other Holders.

 

Section 8.04. Effect
of Headings.

 

The
Article and Section headings herein are for convenience only and shall not affect the construction hereof.

 

Section 8.05. Benefits
of Agreement.

 

Nothing
in this Agreement, express or implied, shall give to any Person (other than the parties hereto, the Holders and their permitted
successors and permitted assigns hereunder) any benefit or any legal or equitable right, remedy or claim under this Agreement
or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of the parties
hereto, the Holders and their permitted successors and permitted assigns; provided, that the Holders shall have no
rights or remedies hereunder except as expressly set forth herein.

 

    -22-

     

    

 

Section 8.06. Governing
Law; Jurisdiction.

 

(a) 
This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect
to any choice or conflict of law principals, whether of the State of Delaware or any other jurisdiction, that would cause the
application of the laws of any jurisdiction other than the laws of the State of Delaware. In any action or suit among any of the
Company, the Wize Subsidiaries, the Rights Agent, the Holders’ Representative and the Holders arising out of or relating
to this Agreement: (a) each of the Company, the Wize Subsidiaries, the Rights Agent, the Holders’ Representative and, to
the extent valid and binding under applicable law, Holders irrevocably and unconditionally consents and submits to the exclusive
jurisdiction and venue of the state and federal courts located in the State of Delaware; (b) if any such action or suit is commenced
in such state court, then, none of the Company, the Wize Subsidiaries, the Rights Agent, the Holders’ Representative and,
to the extent valid and binding under applicable law, the Holders shall object to the removal of such action or suit to any federal
court located in the District of Delaware; and (c) each of the Company, the Wize Subsidiaries, the Rights Agent, the Holders’
Representative or, to the extent valid and binding under applicable law, the Holders irrevocably waives the right to trial by
jury.

 

(b) 
EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN
RESPECT OF ANY SUIT, ACTION OR OTHER PROCEEDING, DIRECTLY OR INDIRECTLY, ARISING OUT OF, UNDER OR RELATING TO THIS AGREEMENT.
EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH PARTY
WOULD NOT, IN THE EVENT OF ANY ACTION, SUIT OR PROCEEDING, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT
IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT, BY, AMONG OTHER THINGS, THE MUTUAL WAIVER AND
CERTIFICATIONS IN THIS SECTION 8.06(b) .

 

Section 8.07. Legal
Holidays.

 

In
the event that a CVR Payment Date shall not be a Business Day, then, notwithstanding any provision of this Agreement to the contrary,
any payment required to be made in respect of the CVRs on such date need not be made on such date, but may be made on the next
succeeding Business Day with the same force and effect as if made on the CVR Payment Date.

 

Section 8.08. Fund.

 

All
funds received by the Rights Agent under this Agreement that are to be distributed or applied by the Rights Agent in the performance
of the services contemplated hereunder (the “Funds”) shall be held by the Rights Agent as agent for
the Holders and the Wize Subsidiaries, or to the extent applicable, the Company deposited in one or more bank accounts to be maintained
by the Rights Agent in its name as agent for the Holders and the Wize Subsidiaries, or to the extent applicable, the Company.
Until paid pursuant to the terms of this Agreement, the Rights Agent will hold the Funds through such accounts in: deposit accounts
of (i) Citi Bank or (ii) other commercial banks with Tier 1 capital exceeding $1 billion or with an average rating above investment
grade by S&P (LT Local Issuer Credit Rating), Moody’s (Long Term Rating) and Fitch Ratings, Inc. (LT Issuer Default
Rating) (each as reported by Bloomberg Finance L.P.). The Rights Agent shall have no responsibility or liability for any diminution
of the Funds, including any losses resulting from a default by any bank, financial institution or other third party, that may
result from any deposit made by the Rights Agent in accordance with this paragraph. The Rights Agent may from time to time receive
interest, dividends or other earnings in connection with such deposits. The Rights Agent shall not be obligated to pay such interest,
dividends or earnings to the Company, the Wize Subsidiaries, any Holder or any other party.

  

    -23-

     

    

 

Section 8.09. Severability
Clause.

 

Any
term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the
validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending
term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction
declares that any term or provision of this Agreement is invalid or unenforceable, the Company, the Wize Subsidiaries, the Holders’
Representative, the Rights Agent agree that the court making such determination will have the power to limit such term or provision,
to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable
and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall
be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the preceding sentence,
the Company, the Wize Subsidiaries, the Holders’ Representative, the Rights Agent agree to replace such invalid or unenforceable
term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business
and other purposes of such invalid or unenforceable term or provision; provided, however, that if such term or provision,
whether modified by the court or the agreement of the or the other parties hereto, shall adversely affect the rights, immunities,
liabilities, duties or obligations of the Rights Agent (in its sole discretion), the Rights Agent shall be entitled to resign
immediately upon written notice to the Company and the Holders’ Representative.

 

Section 8.10. Counterparts.

 

This
Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute
one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties hereto by
electronic transmission, including in PDF format, shall be sufficient to bind the parties to the terms and conditions of this
Agreement.

 

Section 8.11. Entire
Agreement.

 

As
it relates to the Rights Agent, this Agreement and the schedules and exhibits attached hereto represents the entire understanding
of the parties hereto regarding the CVRs and the other transactions contemplated hereby, and this Agreement supersedes any and
all other oral or written agreements made with respect to the CVRs. As it relates to the Company, the Wize Subsidiaries, the Holders’
Representative and the Holders, this Agreement represents the entire understanding of the Company, the Wize Subsidiaries, the
Holders’ Representative and the Holders, regarding the CVRs and the other transactions contemplated hereby, and this Agreement
supersedes any and all other oral or written agreements made with respect to the CVRs. If and to the extent that any provision
of this Agreement is inconsistent or conflicts with the Acquisition Agreement, this Agreement shall govern and be controlling.

 

Section 8.12. Other
Remedies; Specific Performance.

 

Except
as otherwise provided herein, any and all remedies herein expressly conferred upon the Company, the Wize Subsidiaries, the Rights
Agent, the Holders’ Representative and the Holders will be deemed cumulative with and not exclusive of any other remedy
conferred hereby, or by law or equity upon any of them, and the exercise by the Company, the Wize Subsidiaries, the Rights Agent,
the Holders’ Representative or the Holders of any one remedy will not preclude the exercise of any other remedy. The Company,
the Wize Subsidiaries, the Holders’ Representative and the Holders agree that irreparable damage would occur in the event
that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached.
It is accordingly agreed that the Company, the Wize Subsidiaries, the Holders’ Representative and the Holders (acting through
the Holders’ Representative or by consent of the Majority of CVR Holders) shall be entitled to an injunction or injunctions
to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any court of the United States,
the State of Israel or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at
law or in equity, and each of the Company, the Wize Subsidiaries, the Holders’ Representative and the Holders waives any
bond, surety or other security that might be required of any other with respect thereto.

 

Section 8.13. 
No Fiduciary Obligations.

 

Each
party acknowledges and agrees (and the Holders are deemed to agree) that the Holders’ Representative does not owe any fiduciary
duties to either party or any of the Holders.

 

Section 8.14. 
Confidentiality.

 

The
parties hereto agree that all books, records, information and data pertaining to the business of the Rights Agent, including inter
alia, personal, non-public Holder information, which are exchanged or received pursuant to the negotiation or the carrying
out of this Agreement including the fees for services provided hereunder shall remain confidential, and shall not be voluntarily
disclosed to any other person, except (i) as may be required by law, including, without limitation, pursuant to subpoenas from
state or federal government authorities (e.g., in divorce and criminal actions), (ii) as may be required by the Securities Act
of 1933, as amended, or the Securities Exchange Act of 1934, as amended, in each case including the rules and regulations promulgated
thereunder, (iii) as may be required by the rules and regulations of any national securities exchange or over the counter market
on which any of the Company’s securities are then listed or admitted for trading or (iv) with the prior written consent
of the Rights Agent (not to be unreasonably withheld).

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]

 

    -24-

     

    

 

IN
WITNESS WHEREOF, each of the parties has caused this Contingent Value Rights Agreement to be executed on its behalf by its duly
authorized officers as of the day and year first above written. 

  

	WIZE PHARMA, INC.

	 
	 	 	 
	By: 	 	 
	Name:	                  	 
	Title: 	 	 
	 	 	 
	[●],
as Rights Agent

	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:  	 	 
	 	 	 
	[●],
as Holders’ Representative

	 
	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 

  

	Wize NC, Inc.	 
	 	 	 
	By: 	 	 
	Name:	 	 
	Title:	 	 
	 	 	 
	OcuWize Ltd.	 
	 	 	 
	By: 		 
	Name:	 	 
	Title:	 	 

 

    -25-

     

    

 

Schedule
1

 

Rights
Agent Fees and Expenses

 

[Omitted.
The registrant agrees to furnish supplementally a copy of such omitted appendix to the U.S. Securities and Exchange Commission
upon request.]

  

    -26-

     

    

 

Schedule
2

 

Address
for Notices

 

[Omitted.
The registrant agrees to furnish supplementally a copy of such omitted appendix to the U.S. Securities and Exchange Commission
upon request.]

 

    -27-

     

    

 

Schedule
3

 

Authorized
Representatives 

 

[Omitted.
The registrant agrees to furnish supplementally a copy of such omitted appendix to the U.S. Securities and Exchange Commission
upon request.]

 

 

-28-EX-4.2

 Exhibit 4.2 

THIS WARRANT AND THE CLASS A COMMON SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND
SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 
 THIS WARRANT AND THE
CLASS A COMMON SHARES REPRESENTED BY THIS WARRANT ARE SUBJECT TO CERTAIN RESALE RESTRICTIONS PURSUANT TO THE PROVISIONS OF THE SECURITIES ACT (BRITISH COLUMBIA) (THE “SECURITIES ACT”) AND CERTAIN RESTRICTIONS UPON TRANSFER
PURSUANT TO THE TERMS HEREOF AND ANY SECURITIES FOR WHICH THIS WARRANT IS EXCHANGED ARE SUBJECT TO CERTAIN RESALE RESTRICTIONS PURSUANT TO THE SECURITIES ACT AND TO CERTAIN RESTRICTIONS UPON TRANSFER PURSUANT TO THE ARTICLES OF THE COMPANY. 

UNLESS PERMITTED UNDER APPLICABLE SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE THE DATE THAT IS 4
MONTHS AND A DAY AFTER THE LATER OF (i) AUGUST     , 2014 AND (ii) THE DATE THE COMPANY BECOMES A REPORTING ISSUER IN ANY PROVINCE OR TERRITORY IN CANADA. 

THIS WARRANT WILL BE VOID AND OF NO VALUE UNLESS EXERCISED WITHIN THE TIME LIMITS PROVIDED HEREIN. 

WARRANT TO PURCHASE COMMON SHARES 

Company: GENOMEDX BIOSCIENCES INC., a corporation organized under the laws of the Province of British Columbia (the
“Company”). 
 Number of Class A Common Shares of the Company (“Common Shares”): 43,757 (the
“Initial Shares”), plus all Additional Shares (as defined in Section 1.7) which Holder is entitled to purchase pursuant to Section 1.7 

Warrant Price: $1.3712 per share 

Issue Date: August 21, 2014 

Expiration Date: August 21, 2024 See also Section 5.1(b). 

 

	Credit Facility:	 This Warrant to Purchase Common Stock (“Warrant”) is issued in connection
with that certain Loan and Security Agreement of even date herewith between Silicon Valley Bank, the Company and GENOMEDX BIOSCIENCES CORP. (the “Loan Agreement”). 

THIS WARRANT CERTIFIES THAT, for good and valuable consideration, SILICON VALLEY BANK (together with any successor or
permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase the 

  
 1 

 
number of fully paid and non-assessable Common Shares of the Company at the above-stated Warrant Price, all as set forth above and as adjusted pursuant to
Section 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. Reference is made to Section 5.4 of this Warrant whereby Silicon Valley Bank shall transfer this Warrant to its parent
company, SVB Financial Group. 
 SECTION 1. EXERCISE. 

1.1    Method of Exercise. Holder may at any time and from time to time exercise this Warrant, in
whole or in part, by delivering to the Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless
exercise set forth in Section 1.2, a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price
for the Common Shares being purchased. 
 1.2    Cashless Exercise. On any exercise of this
Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Common Shares equal to the value of
this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the Company shall issue to the Holder such number of fully paid and non-assessable Common Shares as are computed using
the following formula: 
  

					
		 	 X = Y(A-B)/A

	 where:
	 		 	
			
		 	 X =
	 	 the number of Common Shares to be issued to the Holder;

			
		 	 Y =
	 	 the number of Common Shares with respect to which this Warrant is being exercised (inclusive of the Common Shares
surrendered to the Company in payment of the aggregate Warrant Price);

			
		 	 A =
	 	 the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and

			
		 	 B =
	 	 the Warrant Price.

 1.3    Fair Market Value. If the Company’s Common Shares are
then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market (a “Trading
Market”), the fair market value of a Common Share shall be the closing price or last sale price of a share of Common Share reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its
Notice of Exercise to the Company. If the Company’s Common Shares are not traded in a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Common Share in its reasonable good faith judgment. 

  
 2 

 1.4    Delivery of Certificate and New Warrant.
Within a reasonable time after Holder exercises this Warrant in the manner set forth in Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Common Shares issued to Holder upon such exercise and, if this
Warrant has not been fully exercised and has not expired, a new warrant of like tenor representing the Common Shares not so acquired. 

1.5    Replacement of Warrant. On receipt of evidence reasonably satisfactory to the Company of the
loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of mutilation, on
surrender of this Warrant to the Company for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount, taking into account all prior exercises and
adjustments. 
 1.6    Treatment of Warrant Upon Acquisition of Company. 

(a)    Acquisition. For the purpose of this Warrant, “Acquisition” means any
transaction or series of related transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company (ii) any merger or consolidation of the Company into or with
another person or entity (other than a merger or consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior
to such merger, consolidation or reorganization, own less than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization; or (iii) any
sale or other transfer by the stockholders of the Company of shares representing at least a majority of the Company’s then-total outstanding combined voting power. 

(b)    Treatment of Warrant at Acquisition. In the event of an Acquisition in which the
consideration to be received by the Company’s shareholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public Acquisition”), and the fair market
value of one Common Share as determined in accordance with Section 1.3 above would be greater than the Warrant Price in effect on such date immediately prior to such Cash/Public Acquisition, and Holder has not exercised this Warrant pursuant to
Section 1.1 above as to all Common Shares, then this Warrant shall automatically be deemed to be Cashless Exercised pursuant to Section 1.2 above as to all Common Shares effective immediately prior to and contingent upon the consummation
of a Cash/Public Acquisition. In connection with such Cashless Exercise, Holder shall be deemed to have restated each of the representations and warranties in Section 4 of the Warrant as the date thereof and the Company shall promptly notify
the Holder of the number of Common Shares (or such other securities) issued upon exercise. In the event of a Cash/Public Acquisition where the fair market value of one Common Share as determined in accordance with Section 1.3 above would be
less than the Warrant Price in effect immediately prior to such Cash/Public Acquisition, then this Warrant will expire immediately prior to the consummation of such Cash/Public Acquisition. 

(c)    Upon the closing of any Acquisition other than a Cash/Public Acquisition defined above, the
acquiring, surviving or successor entity shall assume the obligations of this 

  
 3 

 
Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property as would have been paid for the Common Shares issuable upon exercise of the unexercised
portion of this Warrant as if such Common Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the provisions of this Warrant. 

(d)    As used in this Warrant, “Marketable Securities” means securities meeting
all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or
similar reporting requirements of applicable securities laws in Canada, and is then current in its filing of all required reports and other information under the Act and the Exchange Act or under such applicable securities laws in Canada;
(ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing thereof is then traded in Trading Market,
and (iii) if such Trading Market is a Canada Trading Market, following the closing of such Acquisition, Holder would not be restricted from publicly re-selling all of the issuer’s shares and/or other
securities that would be received by Holder in such Acquisition were Holder to exercise or convert this Warrant in full on or prior to the closing of such Acquisition, or if such Trading Market is a US Trading Market, Holder would be able to
publicly re sell all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise this Warrant in full on or prior to the closing of such Acquisition, except to the extent that any
such restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond six (6) months from the closing of such Acquisition. 

1.7    Number of Common Shares. This Warrant shall be exercisable for the Initial Shares, plus,
upon Silicon Valley Bank making the first Tranche B Growth Capital Advance (as defined in the Loan Agreement) to the Company pursuant to the Loan Agreement, the Additional Shares. As used herein, “Additional Shares” means Forty-Three
Thousand Seven Hundred Fifty-Seven (43,757) Common Shares. 
 SECTION 2. ADJUSTMENTS TO THE COMMON SHARES AND WARRANT PRICE. 

2.1    Share Dividends, Splits, Combinations, Etc. If the Company declares or pays a dividend or
distribution on the outstanding Common Shares payable in securities or property (other than cash), then upon exercise of this Warrant, for each Common Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind
of securities and property which Holder would have received had Holder owned the Common Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding Common Shares by reclassification or otherwise
into a greater number of shares, the number of Common Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the Company combines the outstanding Common Shares by reclassification
or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Common Shares into which this Warrant is exercisable shall be proportionately decreased. 

  
 4 

 2.2    Reclassification, Exchange or
Substitution. Upon any event whereby all of the outstanding Common Shares are reclassified, exchanged, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of
such event, this Warrant will be exercisable for the number, class and series of Company securities that Holder would have received had the Common Shares into which this Warrant is exercisable been outstanding on and as of the consummation of such
event, and subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations
substitutions, replacements or other similar events. 
 2.3    No Fractional Share. No fractional
Common Share shall be issuable upon exercise of this Warrant and the number of Common Shares to be issued shall be rounded down to the nearest whole Share. If a fractional Common Share interest arises upon any exercise of the Warrant, the Company
shall eliminate such fractional Common Share interest by paying Holder in cash the amount computed by multiplying the fractional interest by (i) the fair market value (as determined in accordance with Section 1.3 above) of a full Common
Share, less (ii) the then-effective Warrant Price. 
 2.4    Notice/Certificate as to
Adjustments. Upon each adjustment of the Warrant Price, Common Stock and/or the number of Common Shares into which this Warrant is exercisable, the Company, at the Company’s expense, shall notify Holder in writing within a reasonable time
setting forth the adjustments to the Warrant Price, class and/or number of Common Shares into which this Warrant is exercisable and facts upon which such adjustment is based. The Company shall, upon written request from Holder, furnish Holder with a
certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, class and number of Common Shares (or other securities of the Company, to the extent applicable) into which this Warrant is exercisable in
effect upon the date of such adjustment. 
 SECTION 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY. 

3.1    Representations and Warranties. The Company represents and warrants to, and agrees with, the
Holder as follows: 
 (a)    The initial Warrant Price referenced on the first page of this Warrant is
not greater than the fair market value of the Class B Preferred Shares of the Company as of the Issue Date. 

(b)    All Common Shares which may be issued upon the exercise of this Warrant, shall, upon issuance, be
duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable US and Canada federal,
provincial and state securities laws. The Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital stock such number of securities as will be sufficient to permit the exercise in
full of this Warrant. 
 (c)    The Company’s capitalization table attached hereto as Schedule 1 is
true and complete, in all material respects, as of the Issue Date. 

  
 5 

 3.2    Notice of Certain Events. If the Company
proposes at any time to: 
 (a)    declare any dividend or distribution upon the outstanding Common
Shares, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; 

(b)    offer for subscription or sale pro rata to the holders of the outstanding Common Shares any
additional shares of any class or series of the Company’s stock (other than pursuant to contractual pre-emptive rights); 

(c)    effect any reclassification, exchange, combination, substitution, reorganization or
recapitalization of the outstanding Common Shares; 
 (d)    effect an Acquisition or to liquidate,
dissolve or wind up; or 
 (e)    effect an its initial, underwritten offering and sale of its
securities to the public pursuant to an effective registration statement under the Act (the “IPO”); 
 then, in connection with
each such event, the Company shall give Holder: 
 (1)    in the case of the matters
referred to in (a) and (b) above, at least seven (7) Business Days prior written notice of the earlier to occur of the effective date thereof or the date on which a record will be taken for such dividend, distribution, or subscription
rights (and specifying the date on which the holders of outstanding Common Shares will be entitled thereto) or for determining rights to vote, if any, 

(2)    in the case of the matters referred to in (c) and (d) above at least seven
(7) Business Days prior written notice of the date when the same will take place (and specifying the date on which the holders of outstanding shares of the class will be entitled to exchange their shares for the securities or other property
deliverable upon the occurrence of such event and such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such event giving rise to the notice); and 

(3)    with respect to the IPO, at least seven (7) Business Days prior written notice
of the date on which the Company proposes to file its registration statement or prospectus, as applicable, in connection therewith. 

Company will also provide information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s
accounting or reporting requirements. 
 SECTION 4. REPRESENTATIONS, WARRANTIES OF THE HOLDER. 

The Holder represents and warrants to the Company as follows: 

4.1    Purchase for Own Account. This Warrant and the Common Shares to be acquired upon exercise of
this Warrant by Holder are being acquired for investment for Holder’s 

  
 6 

 
account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act and the applicable securities laws of Canada. Holder also represents
that it has not been formed for the specific purpose of acquiring this Warrant or the Common Shares. 

4.2    Disclosure of Information. Holder is aware of the Company’s business affairs and
financial condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder
further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company
possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access. 

4.3    Investment Experience. Holder understands that the purchase of this Warrant and its
underlying securities involves substantial risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and
its underlying securities and has such knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting
personal or business relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons.

 4.4    Accredited Investor Status. Holder is an “accredited investor” within the
meaning of Regulation D promulgated under the Act and National Instrument 45-106 Prospectus and Registration Exemptions and is purchasing the Warrant pursuant to an exemption from the prospectus
requirements of applicable securities laws. Holder has executed and delivered as principal the Accredited Investor Certificate as set forth in the Loan Agreement. 

4.5    The Act. Holder understands that this Warrant and the Common Shares issuable upon exercise
hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder understands that
this Warrant and the Common Shares issued upon any exercise hereof must be held indefinitely unless subsequently registered under the Act pursuant to an effective registration statement or receipted final prospectus and qualified under applicable
state, provincial or territorial securities laws, or unless exemption from such registration and qualification are otherwise available. Holder is aware of the provisions of Rule 144 promulgated under the Act. 

4.6    Market Stand-off Agreement. The Holder agrees that
the Common Shares shall be subject to the market standoff provisions in Section 2.11 of the Amended and Restated Investor Rights Agreement of the Company dated September 18, 2013. 

4.7    No Voting Rights. Holder, as a Holder of this Warrant, will not have any voting rights until
the exercise of this Warrant. 

  
 7 

 SECTION 5. MISCELLANEOUS. 

5.1    Term and Automatic Conversion Upon Expiration. 

(a)    Term. Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or
in part at any time and from time to time on or before 6:00 PM, Pacific time, on the Expiration Date and shall be void thereafter. 

(b)    Automatic Cashless Exercise upon Expiration. In the event that, upon the Expiration Date, the fair
market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and
as of such date to be exercised pursuant to Section 1.2 above as to all Common Shares (or such other securities) for which it shall not previously have been exercised, and the Company shall, within a reasonable time, deliver a certificate
representing the Common Shares (or such other securities) issued upon such exercise to Holder. 

5.2    Legends. The Common Shares (and the securities issuable, directly or indirectly, upon
conversion of the Common Shares, if any) shall be imprinted with a legend in substantially the following form: 
 THE COMMON
SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE COMMON
STOCK ISSUED BY THE ISSUER TO SILICON VALLEY BANK DATED AUGUST     , 2014, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO
THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 
 THE COMMON SHARES REPRESENTED BY
THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESALE RESTRICTIONS PURSUANT TO THE PROVISIONS OF THE SECURITIES ACT (BRITISH COLUMBIA) AND CERTAIN RESTRICTIONS UPON TRANSFER PURSUANT TO THE TERMS OF THE WARRANT AND PURSUANT TO THE ARTICLES OF THE COMPANY.

 UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE THE DATE
THAT IS 4 MONTHS AND A DAY AFTER THE LATER OF (i) AUGUST     , 2014, AND (ii) THE DATE THE 

  
 8 

 
COMPANY BECOMES A REPORTING ISSUER IN ANY PROVINCE OR TERRITORY IN CANADA. 

DELIVERY OF THIS CERTIFICATE MAY NOT CONSTITUTE “GOOD DELIVERY” IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN
CANADA. A NEW CERTIFICATE, BEARING NO LEGEND, DELIVERY OF WHICH WILL CONSTITUTE “GOOD DELIVERY”, MAY BE OBTAINED FROM THE COMPANY UPON DELIVERY OF THIS CERTIFICATE AND A DULY EXECUTED DECLARATION, IN FORM SATISFACTORY TO THE COMPANY, TO
THE EFFECT THAT THE SALE OF THE SECURITIES REPRESENTED HEREBY IS BEING MADE IN COMPLIANCE WITH RULE 904 OF REGULATIONS UNDER THE 1933 ACT, AS AMENDED. 

5.3    Compliance with Securities Laws on Transfer. This Warrant and the Common Shares issuable
upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Common Shares, if any) may not be transferred or assigned in whole or in part except in compliance with applicable US and Canadian federal,
provincial and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the
Company). The Company shall not require Holder to provide an opinion of counsel if the transfer is to SVB Financial Group (Silicon Valley Bank’s parent company) or any other affiliate of Holder, provided that any such transferee is an
“accredited investor” as defined in Regulation D promulgated under the Act and National Instrument 45 106 Prospectus and Registration Exemptions. Additionally, the Company shall also not require an opinion of counsel if there is no
material question as to the availability of Rule 144 promulgated under the Act. 
 5.4    Transfer
Procedure. After receipt by Silicon Valley Bank of the executed Warrant, Silicon Valley Bank will transfer all of this Warrant to its parent company, SVB Financial Group. By its acceptance of this Warrant, SVB Financial Group hereby makes to the
Company each of the representations and warranties set forth in Section 4 hereof and agrees to be bound by all of the terms and conditions of this Warrant as if the original Holder hereof. Subject to the provisions of Section 5.3 and upon
providing the Company with written notice, SVB Financial Group and any subsequent Holder may transfer all or part of this Warrant or the Common Shares issuable upon exercise of this Warrant (or the securities issuable directly or indirectly, upon
conversion of the Common Shares, if any) to any transferee, provided, however, in connection with any such transfer, SVB Financial Group or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the
name, address and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable); and provided further, that any subsequent transferee other than
SVB Financial Group shall agree in writing with the Company to be bound by all of the terms and conditions of this Warrant. Notwithstanding any contrary provision herein, at all times prior to the IPO, Holder may not, without the Company’s
prior written consent, transfer this Warrant or any portion hereof, or any Common Shares issued 

  
 9 

 
upon any exercise hereof, or any shares or other securities issued upon any conversion of any Common Shares issued upon any exercise hereof, to any person or entity who directly competes with the
Company, except in connection with an Acquisition of the Company by such a direct competitor. 

5.5    Notices. All notices and other communications hereunder from the Company to the Holder, or
vice versa, shall be deemed delivered and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered or certified mail, postage prepaid, (iii) upon actual receipt if given by
facsimile or electronic mail and such receipt is confirmed in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such address as may have
been furnished to the Company or Holder, as the case may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section 5.5. All notices to Holder shall be addressed as follows until the Company
receives notice of a change of address in connection with a transfer or otherwise: 
 SVB Financial Group 

Attn: Treasury Department 

3003 Tasman Drive, HC 215 

Santa Clara, CA 95054 

Telephone: 

Facsimile: 

Email address: 

Notice to the Company shall be addressed as follows until Holder receives notice of a change in address: 

GenomeDx Biosciences Inc. 

#400-311 Water Street 

Vancouver, BC, V6B 1B8 

Attn: Dave Matthews - CFO 

Fax:       

Email: 

5.6    Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated
(either generally or in a particular instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 

5.7    Attorney’s Fees. In the event of any dispute between the parties concerning the terms
and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

5.8    Counterparts; Facsimile/Electronic Signatures. This Warrant may be executed in counterparts,
all of which together shall constitute one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an 

  
 10 

 
original signature page with regards to any agreement subject to the terms hereof or any amendment thereto. 

5.9    Governing Law. This Warrant shall be governed by and construed in accordance with the laws
of the Province of British Columbia and the laws of Canada applicable therein. 

5.10    Headings. The headings in this Warrant are for purposes of reference only and shall not
limit or otherwise affect the meaning of any provision of this Warrant. 
 5.11    Business Days.
“Business Day” is any day that is not a Saturday, Sunday or a day on which Silicon Valley Bank or banks in Vancouver, British Columbia are closed. 

[Remainder of page left blank intentionally] 

[Signature page follows] 

  
 11 

 IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Common
Stock to be executed by their duly authorized representatives effective as of the Issue Date written above. 
 “COMPANY” 

GENOMEDX BIOSCIENCES INC. 
  

			
	 By: 
	 	 /s/ David Matthews

	 Name:
	 	 David Matthews

		 	 (Print)

	 Title:
	 	 Chief Financial Officer & Secretary

	
	 “HOLDER”

	
	 SILICON VALLEY BANK

		
	 By: 
	 	 /s/ David Sanders

	 Name:
	 	 David Sanders

		 	 (Print)

	 Title:
	 	 VP

 APPENDIX 1 

NOTICE OF EXERCISE 

1.    The undersigned Holder hereby exercises its right to purchase
                 the Class A Common Shares of GENOMEDX BIOSCIENCES INC. (the “Company”) in accordance with the attached Warrant To
Purchase Common Shares, and tenders payment of the aggregate Warrant Price for such shares as follows: 
  

	 	☐	 check in the amount of $         payable to order of the
Company enclosed herewith 

  

	 	☐	 Wire transfer of immediately available funds to the Company’s account 

 

	 	☐	 Cashless Exercise pursuant to Section 1.2 of the Warrant 

 

	 	☐	 Other [Describe]
                     

2.    Please issue a certificate or certificates representing the Common Shares in the name specified
below: 
  

					
		 	  
	 	
		 	Holder’s Name (Address)	 	
			
		 	  
	 	
			
		 	  
	 	
		 	(Address)	 	

 3.    By its execution below and for the benefit of the Company, Holder
hereby restates each of the representations and warranties in Section 4 of the Warrant to Purchase Common Shares as of the date hereof. 
  

			
	 HOLDER:
	 	
	
	  

		
	 By:
	 	
                  
                                         
                     

		
	 Name:
	 	
                  
                                         
  

		
	 Title:
	 	
                  
                                         
  

		
	 (Date):
	 	
                  
                                         
                      

 SCHEDULE 1 

Company Capitalization Table 

See attached

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]